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INTRODUCTION 
           Hypertension is one of the leading cause of global burden of 
disease accounting 7.6 million deaths and 92 million DALY as per 2001 
reports. Hypertension increases the risk of CVD significantly twice 
including CHD, CCF renal failure, ischemic and hemorrhagic 
cerebrovascular accident, and peripheral vascular disease. Although 
antihypertensive medications reduces these risks, still huge subset of 
hypertensive patients either remains untreated or not treated adequately.1 
Among the treated groups we have controlled hypertensive patients, who 
are having target blood pressure with the use of less than 3 distinct group 
antihypertensive medications. 
              Resistant hypertension, a clinical problem commonly 
encountered by physicians has an estimated prevalence of 10% to 15% 
among all treated hypertensive patients.2They are more prone for 
cardiovascular events than controlled hypertensives and healthy 
normotensives. 
Platelet size and function is measured by Mean Platelet Volume (MPV). 
We have studies mentioning younger platelets are larger and are more 
thrombotic than smaller ones, which is one of the reason for increased 
ischemic events in hypertensive patients.21 In this study we are going to 
assess whether the mean platelet volume is higher in resistant hypertensive 
patients than in controlled hypertensive and healthy normotensive subjects.
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AIMS & OBJECTIVES 
Primary objective: 
               To estimate and compare mean platelet volume among 
normotensive subjects, controlled and resistant hypertensive patients. 
Secondary objective: 
                    To investigate the association of mean platelet volume with 
systolic & diastolic blood pressure, BMI, serum triglyceride, serum 
creatinine, hemoglobin levels and duration of hypertension. 
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REVIEW OF LITERATURE 
History  
                      The history of hypertension dates back to 2600 BC, when it 
was called as ‘hard pulse disease’ at that time was treated with venous cut 
down, bleeding by leaches & acupuncture methods.3 The modern history of 
hypertension begins with William Harvey, who wrote ‘De motu cordis’ 
that explains circulation of blood in detail.4 In 1733, measurement of blood 
pressure was first established by Stephen Hales of England.   
                        In 1836, Richard Bright found there was an association 
between cardiac hypertrophy and kidney disease, and subsequently kidney 
disease was coined as Bright's disease.5 In 1850 George Johnson found that 
the thickened blood vessels seen in Bright's disease might be an adaptation 
to high blood pressure. 
                        Frederick Akbar Mahommed made first report in 1874 
about elevated blood pressure in a person without evidence of kidney 
disease using a sphygmograph.6 
The concept of hypertensive disease as a generalized disease of 
circulatory system was put forward by Sir Clifford Allbutt, who coined the 
term "hyperpiesia" for hypertension. In 1896 the cuff-based 
sphygmomanometer was introduced by Scipione Riva-Rocci.  
                          Then Nikolai Korotkoff in 1905 improved the technique 
by describing the Korotkoff sounds that are heard with a stethoscope, when 
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the artery is auscultated while deflating the sphygmomanometer cuff. The 
term essential hypertension ('Essentielle Hypertonie') was introduced by 
Eberhard Frank in 1911 to elevated blood pressure for which cause 
couldn’t be attributed. 
                        Paul Dudley White, a cardiologist, in 1937 suggested that 
"hypertension may be a compensatory mechanism which should not be 
tampered with, even if we could control it". Charles Friedberg's textbook 
"Diseases of the Heart" published in 1949, stated that "people with 'mild 
benign' hypertension (defined as blood pressures up to levels of 210/100 
mm Hg) need not be treated". Over the decades with increasing evidence 
from several longitudinal studies, such as the Framingham Heart Study, 
that "benign" hypertension increased cardiovascular disease morbidity and 
mortality, and these risks increased in an exponential manner with 
increasing blood pressure across the spectrum. Later the National Institutes 
of Health sponsored other population studies, which showed that African 
Americans had a larger burden of hypertension and its complications. 
DEFINITIONS 
Resistant hypertension — Resistant hypertension is defined by the 2017 
ACC/AHA (American College of Cardiology/American Heart 
Association ) hypertension guidelines and by the 2013 ESH/ESC 
(European Societies of Hypertension and Cardiology ) as blood pressure 
that remains above the target even after concurrent use of three 
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antihypertensive agents of different groups, One of the those 
antihypertensive medication used should be a diuretic, and all medications 
should be prescribed at optimal doses i.e., more than or equal to fifty 
percent of the maximum recommended antihypertensive dose.8 
 Thus resistant hypertension includes patients who requires concurrent use 
of four or more medications to control hypertension. 
         Patients with RHTN may have increase in both systolic and diastolic 
pressures, among them isolated systolic hypertension is more common. 
Such isolated systolic hypertensive patients are already resistant to therapy, 
treating them become more complicated because intensifying the treatment 
may lead to exaggerated fall of diastolic pressures.  
            Resistant hypertension is not as same as uncontrolled 
hypertension, since RHTN is one of the cause for uncontrolled 
hypertension. Some other causes of uncontrolled hypertension are 
inadequate treatment regimens and pseudoresistance. 
Refractory hypertension  
                                 Refractory hypertension is defined as the failure to 
control blood pressure to goal despite using at least five antihypertensive 
medications at maximum tolerable doses, including thiazides and 
potassium sparing diuretics.9 It is postulated that, this treatment failure in 
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such patients may be due to neurogenic mechanisms like increased 
sympathetic nervous system activity.  
                  In patients who were diagnosed to have resistant hypertension 
initially, it should be confirmed whether he/she is truly having resistant 
hypertension. For that we need to know about these following differential 
diagnoses 
Apparent resistant hypertension  
                Patients with apparent resistant hypertension are those who 
appears to have treatment resistant hypertension (i.e., blood pressure have 
not been controlled even after use of three or more antihypertensive drugs 
or those who require four or more drugs to control their blood pressure), 
but the actual cause may be due to pseudoresistance as enlisted below.10 
Pseudoresistant hypertension  
                        Pseudoresistant hypertension is defined as an uncontrolled 
hypertension that appears as treatment resistant hypertension, but is 
actually due to other confounding factors.  
 Some frequent causes seen in clinical scenario for pseudoresistance are: 
1. Faulty technique in measuring blood pressure (eg: use of an 
inappropriate cuff size).  
2. White coat hypertension 
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3. Poor adherence to dietary and lifestyle advices to lower blood pressure, 
such as a restriction of sodium intake to certain limit, regular physical 
activity 
4. Suboptimal dosage of antihypertensive medications 
5. Poor adherence to antihypertensive therapy. 
 
The following table of blood pressure classification by JNC 8 (same as JNC 7) 
recommendations, based on which we have done study. 
 
PREVALENCE  
                         The true prevalence is not known. A major problem is that 
not all patients with uncontrolled hypertension have resistant hypertension 
as defined above. Many patients are having uncontrolled blood pressure 
because of their poor adherence or inadequate treatment regimens. The 
proportion of hypertensive patients receiving three or more blood pressure 
medications increased from 14 to 24 percent between 1994 and 2004. 
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Possible reasons for the increase in difficult-to-control hypertension 
include increases in the average age and the average weight of the 
population. Data were not given on resistant hypertension.  
RISK FACTORS  
• Higher baseline blood pressure (particularly systolic) 
• Presence of LVH 
• Older age 
• African-American race 
• Chronic kidney disease 
• Obesity 
• Diabetes 
       Potentially reversible factors that contribute to resistant hypertension 
include  
• Lifestyle and diet 
• Suboptimal therapy 
• Medications and herbal preparations that can raise the blood pressure 
• Secondary causes of hypertension 
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CAUSES OF RESISTANT HYPERTENSION 
 
Suboptimal therapy is the most common cause of resistant 
hypertension.11 Mostly Due to the lack of administration of more effective 
antihypertensive drugs and inability to prevent volume expansion with 
adequate diuretics. 
10 
 
 Lifestyle and diet - Obesity, a high-salt diet, physical inactivity, and 
heavy alcohol intake all contribute to hypertension. 
  Extracellular volume expansion - Relative or absolute volume 
expansion is partially responsible for an inability to control hypertension. 
Underlying renal insufficiency, sodium retention due to therapy with 
vasodilators, and/or ingestion of a high-salt diet all may play a role.12 
Secondary causes of hypertension - Patients with resistant hypertension 
are more likely to have an underlying identifiable cause of hypertension 
that is secondary hypertension. The most common causes are  
• Primary aldosteronism  
• Renal artery stenosis 
• Chronic kidney disease 
• Obstructive sleep apnea. 
  Less common causes include  
• Pheochromocytoma 
• Cushing's syndrome 
• Aortic coarctation.11 
 Clinical clues — Secondary hypertension should be considered if the 
patient present with resistant hypertension.  
11 
 
           Primary aldosteronism — Primary aldosteronism is reported in 
10 to 20 percent of patients with resistant hypertension.13, 15 Otherwise 
unexplained hypokalemia is the major clue to the presence of primary 
hyperaldosteronism.14 However, more than 50 percent of patients with 
proven primary hyperaldosteronism are normokalemic at presentation. 
Thus, the absence of hypokalemia does not exclude this disorder. 
RENAL ARTERY STENOSIS  
           Renal artery stenosis is a common cause of resistant hypertension 
and can be due to either atherosclerotic disease or, in younger patients, 
fibromuscular dysplasia. 
CHRONIC KIDNEY DISEASE  
           As renal function declines in patients with chronic kidney disease, 
there is an increasing need for additional antihypertensive medications.16 
Diuretics play a central role. Diuretics should be pushed until the blood 
pressure goal is reached or the patient has attained "dry weight," which, in 
the presence of persistent hypertension, is defined as the weight at which 
further fluid loss leads to either symptoms (fatigue, orthostatic 
hypotension) or decreased tissue perfusion as evidenced by an otherwise 
unexplained elevation in the blood urea nitrogen and/or serum creatinine 
concentration.  
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OBSTRUCTIVE SLEEP APNEA  
               Obstructive sleep apnea is common among patients with 
resistant hypertension who are referred for sleep studies. In three series of 
patients with resistant hypertension who were referred for sleep studies, 
significant obstructive sleep apnea was detected in 71 to 85 percent17 and, 
in one, was significantly more common than in patients with controlled 
hypertension. The severity of sleep apnea correlates with the severity of 
hypertension, and both the incidence and severity of sleep apnea were 
greater in men than women.18, 19, 20 
            Based upon observational studies, screening for obstructive sleep 
apnea should be done in patients with resistant hypertension who have one 
or more of the following risk factors: obesity, loud snoring, and/or daytime 
sleepiness. 
            In recent years, four meta-analyses have also shown that the effect of 
continuous, positive airway pressure therapy on ambulatory BP is very small 
(1–2 mm Hg reduction).55The correlation between HTN and OSA should be 
suspected when there is nocturnal increase in BP found in ABPM. In a 3-year 
follow-up study, have shown no difference in BP or drug usage in patients with 
OSA who either continued or discontinued treatment with positive airway 
pressure therapy.57 The effect in resistant hypertension has not been well-
studied. 
13 
 
                       ABPM helps in classifying the hypertension pattern (dipper, 
nondipper, reverse dipper), which is impossible during home or office 
measurements. That classification gives an opportunity to arrange 
chronotherapy and distinguish patients at a higher cardiovascular risk.58 
PATHOPHYSIOLOGY OF HYPERTENSION 
                                        The arterial blood pressure is determined by Cardiac 
output and peripheral resistance. Cardiac output is directly influenced by 
stroke volume and heart rate; stroke volume is related to contractility of 
myocardium and to the size of the vascular compartment. Peripheral resistance 
is determined by functional and anatomic changes in small arteries and 
arterioles. 
INTRAVASCULAR VOLUME 
                                        Sodium is a predominant present in extracellular 
fluid and is a primary determinant of the extracellular fluid volume. When 
sodium intake exceeds the renal capacity to excrete sodium, vascular 
volume may expand and cardiac output may increase initially. However, 
almost every vascular beds have the capacity to auto regulate blood flow, 
and to maintain constant blood flow in the face of increased arterial 
pressure, resistance within that bed must increase, since  
           Blood flow = pressure across the vascular bed/ vascular resistance 
                                         Sodium containing salts can activate several 
vascular, neural, endocrine/paracrine mechanisms, all of which have the 
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strong potential to increase arterial blood pressure. The effect of sodium on 
blood pressure is related to sodium with chloride; non-chloride salts of 
sodium have little or almost no effect on blood pressure. As arterial 
pressure increases in response to intake of high NaCl, urinary sodium 
excretion increases and sodium balance is maintained at the cost of an 
increase in arterial pressure. The mechanism of “pressure-natriuresis” 
phenomenon may be due to subtle increase in the glomerular filtration rate, 
decrease in absorbing capacity of the renal tubules, and hormonal factors 
like atrial natriuretic factor. In individuals with an impaired ability to 
excrete sodium, greater increase in arterial pressure are required to achieve 
natriuresis and sodium balance. 
 AUTONOMIC NERVOUS SYSTEM  
                                       The autonomic nervous system plays an 
important role in maintaining hypertension through their mediators like 
adrenaline, noradrenaline and dopamine. The receptors are alpha1, alpha 2, 
beta 1, beta 2 and beta 3 receptors. The ANS mediators acts on different 
receptors via feedback mechanisms to regulate blood pressure. The 
activities of these adrenergic receptors are mediated by G proteins and by 
intracellular concentrations of second messengers. The receptor sites are 
relatively specific for both the transmitter substance and for the response 
that receptor site elicits. Alpha Receptors are occupied and activated more 
by norepinephrine than by epinephrine, and the reverse is for beta 
receptors. Alpha 1 Receptors are located on postsynaptic region in smooth 
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muscle and produces vasoconstriction. Alpha 2 Receptors are located on 
presynaptic region of postganglionic nerve terminals that produces 
norepinephrine. 
                             In kidneys, activation of alpha 1 -adrenergic receptors 
increases reabsorption of sodium in renal tubules. Different classes of 
antihypertensive medications either by inhibiting alpha 1 receptors or 
acting as agonists of alpha 2 receptors to reduce systemic sympathetic 
outflow. Activation of myocardial beta 1 receptors stimulates the rate and 
strength of cardiac contraction and subsequently increases cardiac output. 
Beta 1 Receptor activation also stimulates renin release from the kidneys.  
                    Many reflexes alter blood pressure on minimal basis. Arterial 
baroreflex is mediated through specialized stretch receptors in the carotid 
sinuses and the aortic arch. The blood pressure increases as firing rate of 
these baroreceptors increases and as a result, there is decrease in 
sympathetic outflow and results reduction in arterial blood pressure and 
heart rate. This is the major mechanism which results in rapid buffering of 
acute fluctuations of arterial blood pressure that may occur during 
physiologic stress, change of posture or behavior and also changes in blood 
volume. 
RENIN-ANGIOTENSIN-ALDOSTERONE  
                   The renin-angiotensin-aldosterone system helps in regulating 
blood pressure mainly via the angiotensin II which is a vasoconstrictor and 
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the sodium retaining properties of aldosterone. Renin, an aspartyl protease 
which is synthesized as an inactive precursor called prorenin. Most renin 
circulating is synthesized in the renal afferent arteriole. Prorenin may be 
secreted directly into the circulation or may be as active renin after 
activation within secretory cells.  
 Renin secretion is stimulated by 
1.  Reduced sodium chloride transport in the distal part of thick ascending 
limb of the loop of henle present near the afferent arteriole (macula densa). 
2.  Reduced stretch or pressure in the renal afferent arteriole (baroreceptor 
mechanism). 
3. Autonomic nervous system via beta 1 receptors stimulating renin-secreting 
cells. 
                                 Similarly, renin secretion is inhibited by increased 
sodium delivery to the distal part of thick ascending limb of the loop of 
henle, by increased stretch or pressure within the afferent arterioles of 
kidney, and by beta 1 receptor inhibition. Potassium ion is an important 
determinant of aldosterone production and its secretion may be reduced in 
individuals with low serum potassium. Aldosterone a potent 
mineralocorticoid that acts by ENaC (amiloride-sensitive epithelial sodium 
channels) on the apical surface of the principal cells in the collecting duct 
of kidneys increases sodium reabsorption. Electrical charge is retained by 
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exchanging potassium and hydrogen ions for sodium. Increased 
aldosterone secretion will result in alkalosis and hypokalemia.  
               Mineralocorticoid receptors are expressed in a multiple regions 
apart from kidneys.  Mineralocorticoid receptor activation in these areas 
results in oxidative stress, as a consequence it produces structural and also 
functional changes in the blood vessels, heart, kidneys leading to vascular 
inflammation and remodeling, fibrosis of myocardial tissue, left ventricular 
hypertrophy and nephronosclerosis.  
                 Increased activity of the RAAS not always results in 
hypertension. In situations like low intake of sodium chloride or to 
intravascular volume depletion, blood pressure and volume are maintained 
by increased activity of the renin-angiotensin aldosterone axis. In volume 
overload states like CHF and cirrhosis there will be secondary hyper 
aldosteronism. 
VASCULAR MECHANISMS  
                       Intra lumen radius and compliance of resistance arteries are 
the primary determinants of arterial pressure. Resistance to blood flow 
changes inversely with the fourth power of the radius. As a result, even a 
small decrement in lumen size significantly increase resistance. The effect 
of hypertension on vascular system are structural, mechanical, or 
functional changes leads to reduced lumen radius of small arteries and 
arterioles.  
18 
 
                                Remodeling indicates geometric changes in the vessel 
wall without alterations in vessel volume. Hypertrophic vascular 
remodeling causes decreased lumen size and, henceforth increase in 
peripheral vascular resistance. Lumen diameter is closely associated with 
elasticity of the vessel wall. Vessels with more elasticity can accommodate 
sudden rise of intravascular volume with relatively subtle changes in 
pressure, whereas in a rigid vascular wall, a small rise in blood volume 
produces a relatively large elevation of pressure.  
                          Hypertension causes stiffening of arterial wall due to 
arteriosclerosis, and decreased vascular compliance results in higher 
systolic blood pressures and wide pulse pressures. Cardiac output and 
peripheral resistance determines the mean arterial pressure, but pulse 
pressure is influenced by functional properties of large arteries and the 
timing and amplitude of the incident and reflected waves. Raised stiffness 
of these arteries results in increased pulse wave velocity of both these 
waves. 
END ORGAN DAMAGES BY HYPERTENSION  
CENTRAL NERVOUS SYSTEM 
                               Globally stroke is the one of the frequent cause of 
death. It was estimated that it contributes to around 5 million deaths per 
annum, also it accounts to 15 million morbidities. Resistant hypertension is 
the strongest risk factor for cerebrovascular accident. Almost 85% of 
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cerebrovascular accidents are due to ischemia, and the remaining 15% are 
due to hemorrhage either in intra cerebral or subarachnoid regions.  CVA 
incidence rises proportionately with elevated blood pressure levels, more 
particularly related to systolic blood pressure in persons >65 years. 
Treating hypertension appropriately leads to reduction in the incidence of 
both types of CVA. 
                       Several longitudinal studies suggests association between 
hypertension in middle-age and cognitive decline in their old age.  
Dementia and impaired cognition due to hypertension and may be a result 
of a single or multiple lacunar infarcts resulting in subcortical white matter 
ischemia. Several randomized control trials suggest there was beneficial 
effect on cognitive function by appropriate antihypertensive therapy. 
                       The innate protective feature of Cerebral blood circulation, 
which keeps blood flow unaltered over a vast range of blood pressures 
(MAP of 50–150 mmHg) through a process called auto regulation. In 
malignant hypertension patients, there will be failure of this auto regulation 
of cerebral blood flow, resulting in vasodilation and high perfusion. This 
auto regulatory failure results in a clinical syndrome called ‘hypertensive 
encephalopathy’ may include the following signs and symptoms like 
severe headache (predominantly in occipital region), nausea and vomiting 
(projectile in nature), focal neurologic deficits, and altered mental status. If 
they left untreated, hypertensive encephalopathy patients may worsen to 
stupor, coma, seizures, and even death in few hours. Meanwhile close 
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differential diagnoses like CVA, meningitis, space occupying lesions, 
trauma, delirium tremens, intoxications and increased intracranial tension 
should be ruled out. 
 KIDNEY  
                            Primary renal disease is the most common cause of 
secondary hypertension. The unique feature of kidneys in hypertension is 
both a cause and target for it. Pathophysiology of renal-related 
hypertension is because of their reduced capacity to excrete sodium, 
increased renin secretion in relation to volume status, and SNS over 
activity. 
                            Renal failure due to hypertension is more avidly related 
to systolic blood pressure than diastolic value, blacks than white people. 
Risk of ESRD increases when there is persistently elevated BP above the 
optimal value. 
                               Atherosclerosis in hypertension associated vascular 
lesions in the kidneys affects pre-glomerular arterioles, consequently 
leading to ischemic changes in the both glomerular and post-glomerular 
structures. Hyperperfusion occurring in hypertension can directly cause 
glomerular injury. As these glomerular insult progresses, it will lead to 
failure of autoregulation in blood flow further to glomeruli causing 
hyperfiltration initially, hypertrophy and finally FSGS.  
21 
 
                             The persistent malignant hypertension and treatment 
resistant hypertension may further cause fibrinoid necrosis of the afferent 
arterioles, extending into the glomerulus, and may eventually end up in 
focal necrosis of the glomerular tuft. 
               Clinically, albumin/creatinine ratio (ACR) in a random urine 
sample is calculated to find whether there is any macro-albuminuria (ACR 
>300 mg/g) or micro-albuminuria (ACR between 30–300 mg/g). Both are 
not only early markers of kidney injury and also risk factors for 
cardiovascular disease and progression of renal disease.  
 PERIPHERAL ARTERIES 
                       Blood vessels are the primary target organ for 
atherosclerosis due to chronic resistant hypertension. It also contributes to 
the pathogenesis of hypertension. Vascular disease is a major contributor 
to cardiac diseases, CVA and CKD. Resistant hypertensive patients with 
peripheral arterial disease of the extremities are at higher risk for 
cardiovascular disease in near future.  
                   Usually patients with milder form of stenotic lesions of the 
lower extremities may be symptom free initially. Classical symptom of 
PAD is the intermittent claudication pain. Clinically PAD can be 
diagnosed by a simple approach called ankle-brachial index (ABI). It is 
defined as the ratio of ankle to brachial (arm) systolic blood pressure, a 
noninvasive mode of assessment. 
22 
 
                    The diagnosis of PAD is made when ankle-brachial index is 
<0.90 and is associated with >50% lumen stenosis in any one major vessel 
in lower limb. An ABI <0.80 is related to hypertension, especially systolic 
blood pressure. 
TREATMENT RECOMMENDATIONS  
                                     Resistant hypertension is multifactorial in etiology. 
Initial step of RHTN treatment is identification and reversal of lifestyle 
factors contributing to treatment resistance. Accurate diagnosis and 
appropriate treatment of secondary causes. Lifestyle changes, including 
regular exercise; weight loss; ingestion of a high-fiber, low-salt, low-fat 
diet; and moderation of alcohol intake should be encouraged. If 
Obstructive sleep apnea is present, should be treated. 
23 
 
 
 
 
 
DASH: Dietary Approaches to Stop Hypertension. 
 
 
 
 
Modification Recommendation 
Approximate systolic BP 
reduction, range* 
Weight reduction Maintain normal body weight (BMI, 
18.5 to 24.9 kg/m2) 
5 to 20 mmHg per 10 kg weight 
loss 
Adopt DASH 
eating plan 
Consume a diet rich in fruits, vegetables, 
and low-fat dairy products with a 
reduced content of saturated and total fat 
8 to 14 mmHg 
Dietary sodium 
reduction 
Reduce dietary sodium intake to no more 
than 100 mEq/day (2.4 g sodium or 6 g 
sodium chloride) 
2 to 8 mmHg 
Physical activity Engage in regular aerobic physical 
activity such as brisk walking (at least 30 
minutes per day, most days of the week) 
4 to 9 mmHg 
Moderation of 
alcohol 
consumption 
Limit consumption to no more than two 
drinks per day in most men and no more 
than one drink per day in women and 
lighter-weight persons 
2 to 4 mmHg 
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AGENTS THAT CAN INTERFERE WITH BLOOD PRESSURE 
CONTROL 
              
                    
Nonpharmacologic treatment of resistant hypertension includes 
the identification and reversal of possible contributing factors with measures 
including weight loss if overweight, regular exercise, a low-salt diet, and 
moderation of alcohol intake. Patients diagnosed with secondary causes of 
hypertension should be referred as needed to appropriate specialists, and, if 
present, obstructive sleep apnea should be treated. Medications that may be 
contributing to hypertension should be reduced, withdrawn, or avoided, if 
possible. Secondary causes of hypertension should be considered and, if 
present, treatment should be given. 
              The pharmacologic treatment of resistant hypertension involves 
combination of three or more drugs. Some patients have a specific 
indication for a class of drugs (eg, beta blocker or nondihydropyridine 
Non-narcotic analgesics (nonsteroidal anti-inflammatory agents, selective COX-2 
inhibitors, aspirin) 
Sympathomimetic agents (decongestants, diet pills, cocaine) 
Stimulants (methylphenidate, dexmethylphenidate, dextroamphetamine, amphetamine, 
methamphetamine) 
Alcohol 
Oral contraceptives 
Cyclosporine 
Erythropoietin 
Natural licorice 
Herbal compounds (ephedra or ma huang) 
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calcium channel blocker for rate control in atrial fibrillation). If there is no 
such indication, the preferred three-drug regimen consists of an 
angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor 
blocker (ARB), a long-acting calcium channel blocker such as amlodipine, 
and a long-acting thiazide diuretic, preferably chlorthalidone. Among 
patients with an estimated glomerular filtration rate of less than 
30 mL/min per 1.73 m2, a loop diuretic, such as furosemide or torsemide, 
is usually necessary for effective volume control.  
                   In patients with persistent uncontrolled hypertension despite 
the above three-drug regimen in optimal dose, adding spironolactone is 
suggested. It should be begin at 12.5 mg/day and titrate up to, but not 
above, 50 mg/day in the absence of proven primary aldosteronism. 
Monitoring of serum potassium levels for both hypokalemia and 
hyperkalemia are necessary if chlorthalidone and spironolactone are used. 
For patients who cannot tolerate spironolactone, eplerenone  and  amiloride 
are alternatives. In patients who are still hypertensive, adding a 
vasodilating beta blocker is recommended. Alternatives include a long-
acting, centrally acting agent such as guanfacine or a clonidine transdermal 
patch.Among patients who remain resistant, a direct vasodilator such 
as hydralazine for women or minoxidil for men may be used. 
                      Some patients with resistant hypertension are being treated 
with a three-drug regimen different from the preferred regimen of an 
angiotensin inhibitor, long-acting dihydropyridine calcium channel 
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blocker, and a long-acting thiazide diuretic.  If the patient is 
on hydrochlorothiazide, switch to chlorthalidone and then add other drugs, 
as necessary. If the current regimen includes a drug not from the three 
recommended drug classes, we add the missing preferred drug and assess 
the response. We do not discontinue any drugs, as long as they are well 
tolerated, before achieving blood pressure control. 
STRATEGIES FOR ADDING ANTIHYPERTENSIVES 
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EVIDENCE BASED DOSING OF ANTIHYPERTENSIVE 
AGENTS56 
 
SURGICAL TREATMENT OF RESISTANT HYPERTENSION 
1. Renal denervation 
In some patients, the use of maximal doses of antihypertensive drugs 
and exclusion of the secondary etiology of HTN did not result in 
reaching target BP values. In such cases Denervation treatment was tried 
based on a correlation between the kidney-related effects of SNS 
activity and the pathophysiology of hypertension. But, SIMPLICITY 
HTN 3 showed that renal denervation seems to have a non-favorable 
impact on morbidity-mortality.59 
2. Electrical stimulation of the carotid sinus baro receptors. 
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PLATELETS 
Platelets are small anucleate cells that play a critical role in 
haemostasis and thrombosis.23 Platelets were described by Addison in 1841 
as extremely minute granules in clotting blood and were termed platelets 
by Bizzozero, who observed their adhesive qualities as increased stickiness 
when a vascular wall is damaged. They are formed from the cytoplasm of 
megakaryocytes and have a characteristic discoid shape. Platelets are 
released from the ends of megakaryocytes as oval discs with average size 
of 2 microns. Younger platelets have greater functional ability. Each 
megakaryocyte forms 103 platelets and 1011 platelets are replenished 
daily.24 
PLATELET FORMATION 
MEGAKARYOCYTE DEVELOPMENT. 
                                   Megakaryocytes are rare myeloid cells (constituting 
less than 1% of these cells) that reside primarily in the bone marrow but 
are also found in the lung and peripheral blood. In early development, 
before the marrow cavities have enlarged sufficiently to support blood cell 
development, megakaryopoiesis occurs within the fetal liver and yolk sac. 
Megakaryocytes arise from pluripotent stem cell that develop into 2 types 
of precursors, burst-forming cells and colony-forming cells, both of which 
express the CD34 antigen.25 Thrombopoietin (TPO), the primary regulator 
of thrombopoiesis, is currently the only known cytokine required for 
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megakaryocytes to maintain a constant platelet mass. TPO is thought to act 
in conjunction with other factors, including IL-3, IL-6, and IL-11, although 
these cytokines are not essential for megakaryocyte maturation.25 
THE FLOW MODEL OF PLATELET FORMATION.  
                    Despite the identification of platelets over 120 years ago, 
there is still little consensus on many of the mechanisms involved in platelet 
biogenesis. However, recent evidence supports a modified flow model of 
platelet assembly. In this model, platelets are assembled along essential 
intermediate pseudopodial extensions, called proplatelets, generated by the 
outflow and evagination of the extensive internal membrane system of the 
mature megakaryocyte. In 1906, Wright introduced the initial concept that 
platelets arise from megakaryocyte extensions when he described the 
detachment of platelets from megakaryocyte pseudopods. Almost a century 
later, studies on megakaryocytes producing platelets in vitro have revealed the 
details of platelet assembly and have led us back to the classical proplatelet 
theory of platelet release in which platelets fragment from the ends of 
megakaryocyte extensions. The assembly of platelets from megakaryocytes 
involves an elaborate dance that converts the cytoplasm into 100 to 500 
microns long branched proplatelets on which the individual platelets develop. 
The proplatelet and platelet formation process generally commences from a 
single site on the megakaryocyte where 1 or more broad pseudopodia form. 
Over a period of 4 to 10 hours, the pseudopodial processes continue to 
elongate and become tapered into proplatelets with an average diameter of 2–4 
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microns. Proplatelets25 are randomly decorated with multiple bulges or 
swellings, each similar in size to a platelet, which gives them the appearance 
of beads connected by thin cytoplasmic strings. The generation of additional 
proplatelets continues at or near the original site of proplatelet formation and 
spreads in a wavelike fashion throughout the remainder of the cell until the 
megakaryocyte cytoplasm is entirely transformed into an extensive and 
complex network of interconnected proplatelets. The multilobed nucleus of 
the megakaryocyte cell body is compressed into a central mass with little 
cytoplasm and is eventually extruded and degraded. Platelet-sized swellings 
also develop at the proplatelet ends and are the primary sites of platelet 
assembly and release, as opposed to the swellings along the length of the 
proplatelet shaft. The precise events involved in platelet release from 
proplatelet ends have not been identified.                           
Anatomy of a proplatelet. 
                           Differential interference contrast image of proplatelets 
on a mouse megakaryocyte in vitro. Some of the hallmark features of 
proplatelets, including the tip, swellings, shafts, and a branch point, are 
indicated. 
PLATELET LIFE SPAN 
                      Normally, platelets circulate in blood with an average 
lifespan of 7-10 days. Platelets are lost from circulation by two mechanisms: 
either by senescence or by random removal in endothelial supportive functions 
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of a fixed fraction of platelets amounting to 7.1 x 109/l/day. Senescent platelets 
are removed primarily by macrophages in the spleen, although the larger 
blood flow through the liver allows severely damaged platelets to be removed 
more quickly by hepatic macrophages is assumed that when aging, platelets 
contain decreased levels of sialic acid and they accumulate surface IgG.26 
LIGHT MICROSCOPY 
                           Light microscopy of Wright-stained smears reveals 
platelets are small, anucleate fragments with occasional reddish granules, 
measuring approximately 2 microns in diameter with a volume of 
approximately 8fl27, 28 and exhibiting considerable variation in size and shape. 
ELECTRON MICROSCOPY AND SUB-CELLULAR FEATURES 
                             Platelets exist in two distinct forms, resting and 
activated, with the resting state marked by baseline metabolic activity and the 
activated form resulting from agonist stimulation (i.e., response to thrombin) 
because platelets change their structure during the resting to activated 
transition. In describing detailed platelet anatomy, most information is derived 
from transmission electron microscopy, and platelet structure is classified into 
four general areas: the platelet surface, membrane structures, cytoskeleton and 
granules.29 
PLATELET SURFACE 
Plasma Membrane: The platelet plasma membrane separates intra- from 
extracellular regions and, in thin sections, exhibits a typical 20 nm thick 
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trilaminar structure,31 whose overall appearance does not differ from that of 
other blood cells.30 However this unit membrane of platelets is exceptionally 
complex in composition, distribution, and function, incorporating a number of 
glycoproteins and lipids into its phospholipid bi-layer and integrating a variety 
of extra and intra-platelet events such as permeability, agonist stimulation, and 
platelet adhesion, activation/secretion, and aggregation.32 
Glycocalyx: A fuzzy layer of lipids, sugars, and proteins. 15-20 nm 
thick, coats the outside surface of the platelet plasma membrane, including 
surface connected canalicular system (SCCS), and interacts with both the 
plasma and the cellular components of the blood and blood vessels. Termed 
the platelet glycocalyx,33 the layer provides a transfer point for plasma 
proteins such as fibrinogen as they are taken up into secretory granules by 
endocytosis.34 The glycocalyx contains glycoproteins, glycolipids, 
mucopolysaccharides, and absorbed plasma proteins35 and produces a net 
negative surface charge mainly due to sialic acid residues on certain protein 
such as gp Ib.36 This charge is thought to minimize attachment of circulating 
platelets to each other and to vessels.37 
PLATELET MEMBRANOUS SYSTEMS 
                                Platelets have features of muscle related cells in 
terms of their high content of their actin and their contractile response during 
activation. Similar muscle like qualities found in the two membranous systems 
of platelets, the SCCS and the dense tubular system, which resemble 
transverse tubules and sarcotubules respectively. 
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PLATELET CYTOSKELETON 
                         Both the shape of platelets and their ability to contract 
and spread depend on a cytoplasmic frame work of monomers, filaments, and 
tubules that constitute the cytoskeleton.38 The cytoskeleton can direct platelet 
shape change, send out extracellular extensions, collect and then extrude 
secretory granules, and affect surface activity. These varied functions are 
performed by three distinct structures: first, the membrane skeleton, which 
buttresses the inner side of the plasma membrane; second, the mass of actin 
and intermediate filaments, which fills the cytoplasm (cytoplasmic actin 
filaments; also termed the sol-gel zone); and third, the circumferential 
microtubule band, which encircles the substance of the platelet to produce the 
resting disc like form.38, 39 
PLATELET GRANULES AND ORGANELLES 
PLATELET GRANULES 
                    Normal platelet function appears to require some 
amplification or accentuation of any given stimulus to obtain an appropriate 
response. Accordingly, platelets possess secretory granules and mechanisms 
that serve this purpose by releasing additional stimulatory materials, 
previously sequestered within the resting platelet. Two main secretory 
granules, the alpha granules and the dense bodies appear to be the main 
effectors with their highly reactive and readily available contents [i.e. 
adenosine diphosphate (ADP) and fibrinogen].40 Platelet granule secretion 
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begins with a dramatic increase in platelet metabolic activity, set off by a wave 
of calcium release and marked by increased adenosine phosphate (ATP) 
production.41, 42 
ORGANELLES: MICROPEROXISOMES, COATED VESICLES, 
MITOCHONDRIA, AND GLYCOGEN 
       Microperoxisomes are rare, small (90 nm in diameter) granules, 
demonstrable with alkaline di-amino benzidine due to their catalase activity.43 
The structure may participate in the synthesis of platelet-activating factor, but 
its ultimate fate within the platelet cytoplasm is unknown.44 Coated vesicles 
are 70 to 90 nm in diameter platelet organelles, distinguished by their electron 
dense bristle coat. The polyhedral surface coat is composed of clathrin, and 
special staining reveals that the same coat that is in the plasma and SCCS 
membrane is found on the coated pits and vesicles themselves. Mitochondria 
in platelets are similar, with the exception of their smaller size, to those in 
other all types. There are approximately seven per human platelet, and they 
serve as the site for the actions of the respiratory chain and the citric acid 
cycle. Glycogen is found in small particles or in masses of closely associated 
particles, playing an essential role in platelet metabolism.45 
PLATELET FUNCTION 
              The functions of platelets include adhesion, shape change and 
spreading, aggregation, secretion, procoagulant activity, and clot retraction. 
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ADHESION: The initiating event following vascular damage is platelet 
adhesion to exposed sub endothelial matrix proteins. The platelet glycoprotein 
receptors which mediate adhesion are dependent on the rate of shear. 
Adhesion applies also to recruitment of circulating platelets into the 
thrombus.23 
SHAPE CHANGE AND SPREADING: Upon activation, platelets 
become spherical and extend pseudopodia to enable them to attach to other 
platelets and to the vessel wall. The transition to a sphere increases their 
optical density is termed  ‘shape change’, although this term should be used 
with caution unless supported by scanning electron microscopy, as an increase 
in density can also be brought about in other ways. Shape change is mediated 
by phosphorylation of myosin light chains, either as a consequence of 
elevation in intracellular Calcium ions, which activate myosin light chain 
kinase, or through inhibition of myosin light chain phosphatase, which is 
regulated downstream of Rho kinase 
AGGREGATION: Aggregation is used to describe cross-linking of 
platelets through binding of fibrinogen, or other bivalent or multivalent 
ligands such as vWF to the integrin IIb on adjacent cells. 
PROCOAGULANT ACTIVITY: A critical function of platelet 
activation is to provide a negatively charged phospholipid surface for the 
assembly of two multi protein complexes that form a vital part of the 
coagulation cascade, namely the tenase and prothrombinase complexes. The 
formation of the negatively charged lipid surface on activated platelets is 
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commonly described as antiphospholipid exposure or procoagulant activity. It 
is formed by the movement of phosphatidyl serine from the inner to the outer 
leaflet of the platelet membrane. 
PLATELET-DERIVED MICROPARTICLES: Platelet-derived 
microparticles are generated during platelet activation and are usually seen 
together with an increase in procoagulant activity. The formation of platelet 
microparticles also requires Ca2+ entry and is readily seen in response to 
stimulation by Ca2+ ionophore but requires high agonist concentrations and 
favourable conditions for them to be formed upon receptor activation. 
CLOT RETRACTION: It has been known for more than two centuries 
that blood clots retract over a time course of minutes to hours, a process that is 
termed clot retraction. This event helps platelet rich thrombi to withstand the 
high shear forces found in small arterioles and in other vessels. Clot retraction 
can be readily measured in thrombin-stimulated platelet-rich plasma by taking 
aliquots of the volume of plasma over time after addition of thrombin. 
Thrombin rapidly generates a blood clot that fills an aggregometer tube but 
which gradually reduces to almost 20% of its original volume over a course of  
60 minutes. 
PLATELET INDICES 
The quantification of platelet count in peripheral blood is a well 
recognized tool. Similar to RBC, several indices have been derived from 
platelets, with the most commonly used being the mean platelet volume 
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(MPV) and platelet distribution width (PDW). Recent advances in automated 
blood cell analysers have made it possible to measure various platelet 
parameters such as PDW, MPV, PCT and P-LCR, which provide some 
important information but are not yet accepted for routine clinical use. 
MEAN PLATELET VOLUME (MPV) 
                    Measurement of peripheral blood platelet counts tells us 
little about platelet related haemostatic function unless the platelet count is 
particularly low. However, most haematology analysers measure another 
platelet parameter, the mean platelet volume which can give useful clinical 
and pathophysiological information about patients and vascular diseases.46 
                   MPV appears to be a marker, or even a determinant, of 
platelet function. Large platelets are more reactive than small platelets in vitro. 
They preferentially and more rapidly aggregate to platelet agonist including 
ADP, collagen and adrenaline produce more prothrombotic and vasoactive 
factors including arachidonic acid metabolites (eg. Thromboxane A2), 
serotonin, beta thromboglobulin and ATP, contains more dense granules, and 
have higher LDH activity. They are associated with a decreased bleeding time 
(BT; a measure of in vivo haemostatic function). 
                     MPV correlates with platelet aggregation, whether 
measured in platelet rich plasma or whole blood, populations of subjects or in 
some disease states, eg. Diabetes mellitus. Large platelets also express 
increased levels of adhesion molecules. eg. P- selectin, GP IIb/IIIa although 
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the surface density of these glycoproteins is usually constant independent of 
platelet volume. 
THE MEGAKARYOCYTE-PLATELET-HAEMOSTATIC AXIS 
                                 Platelets are anucleate cells and, as such, have little 
or no protein synthetic capacity. Platelets are heterogeneous regarding their 
size, density and haemostatic potential. It used to be thought that platelet size 
decreased with age, but more recent evidence suggests that MPV and other 
platelet parameters and, therefore, platelet protein content and reactivity, are 
determined primarily at or before thrombopoiesis by the platelet precursor 
cell, the MK. MK‘s are unique amongst mammalian cells in that they are 
polyploid. That is to say they can redouble their chromosomal DNA content 
without subsequent full mitotic cell division, a process termed endomitosis. 
MK‘s undergo varying numbers of endomitotic cycles to produce a population 
of cells whose ploidy ranges from 4N to 128N (where 2N represents the 
normal diploid state), with 16N being the modal ploidy in the majority of 
mammals studied thus far. Each MK produces about 1000 to 2000 platelets, 
probably by cytoplasmic fragmentation of MKs in the pulmonary circulation.47 
Measurements of platelet and MK parameters in man suggest that they are so 
closely linked that they can be considered a single system: the megakaryocyte-
platelet haemostatic axis (MPHA). For example, in normal individuals the 
platelet count is inversely proportional to MPV; platelet mass (the product of 
MPV and platelet count) is a near constant; platelet mass correlates with BT; 
and BT is inversely proportional to MK ploidy and size. When acute platelet 
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destruction occurs in the absence of platelet production MPV increases but 
MK ploidy remains unchanged; when platelet production is increased alone 
MK ploidy is increased; and when platelet destruction and production co-exist 
there is an increase in both MPV and MK ploidy. Thus, it would appear that 
MPV and MK ploidy can change together or independently of each other in 
response to varying haemostatic demands. This has led to the postulation that 
regulation of MPV and MK ploidy (and therefore platelet count) is under 
separate hormonal control. Variations in MPV are a result of a change in the 
rate of platelet destruction, whereas altered MK ploidy, and concomitant 
changes in MK size and cytoplasmic volume are associated with a change in 
the rate of platelet production. 
MEASUREMENT OF PLATELET VOLUME 
                            The optimal method for measuring platelet volume 
utilises changes in either electrical impedance (as used in Coulter haematology 
analysers) or light diffraction (as used by Technicon) when a platelet passes 
through a narrow aperture. Alternative and less satisfactory methods include 
semi-quantitative measurement of diameter on platelet smears, or using flow 
cytometry. 
                             In the Coulter series, cells held in fluid suspension 
are flown through a small aperture, thereby creating a change in voltage 
proportional to particle size. A raw histogram is generated, and a log-normal 
curve is fitted to the data. Platelet count is derived from this together with the 
MPV, which is calculated by numerical integration. 
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                    Similarly, the Sysmex analyzer used in our study measures 
parameters with cells in fluid suspension, although in addition the cells are 
hydro dynamically focused, ensuring that cells travel in a straight line through 
the aperture. This prevents cells flowing through at the edge of the aperture 
and causing spurious changes in the electrical field. It also differs from 
Coulter in that the upper and lower discriminators are both mobile.48 The 
distribution curve obtained is thus the actual data and not a fitted curve. MPV 
is calculated from the curve by a formula (MPV (fL)= Pct (%)x1000 ÷ 
Plt(x103/micro litre)). Complete blood count specimens are usually anti 
coagulated in EDTA which causes platelet to swell in a time dependent 
manner. Most of the increase in MPV occurs during the first 1.5 hours but the 
process continues over the next 24 hrs. EDTA is thought to increase 
intracellular cyclic AMP and change plasma membrane permeability. This 
situation is further complicated since analyzers utilizing light diffraction 
measure particle size by assessing optical density. These analyzers record a 
decreasing MPV with time since platelet swelling results in a lower optical 
density. As a result, studies reporting raw MPV measurements made in EDTA 
are of questionable clinical or research value unless MPV is assessed at a 
consistent time following phlebotomy, or once the swelling has ceased at 24 
hrs. In contrast MPV measured in high concentration sodium citrate does not 
change with time and hence considered as the gold standard. 
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NORMAL VALUES FOR MPV 
The normal range for platelet volume has yet to be adequately 
determined, but studies measuring MPV in sodium citrate in normal subjects 
suggest a approximately normal range of 4.5 – 8.5 fl with a mean of 6.5 fl. 
The day to day variation in MPV is small (CV=2.1%) compared with platelet 
count (CV = 6.1%). 
MPV AND ANTIPLATELET DRUGS 
                                Platelet aggregation is an essential step in 
physiological hemostasis and is involved in vascular pathology such as 
atherosclerosis, arterial thromboembolism, unstable angina pectoris, 
myocardial infarction, transitory ischemic attacks of the brain and stroke. The 
inhibition of platelet aggregation, e.g. by aspirin, has become an important 
treatment for unstable angina pectoris and transitory ischemic attacks and the 
secondary prevention of myocardial infarction and stroke. Aspirin inhibits 
platelet aggregation through an irreversible inhibition of the cyclooxygenase. 
It is not known whether this impairment of platelet function has an influence 
on the feedback control system of platelet production and hence on platelet 
count and platelet volume. 
MPV AND AGE 
                     It used to be thought that the platelet size decreased with 
age, but more recent evidence suggests that MPV and other platelet parameters 
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and therefore platelet protein content and reactivity, are determined primarily 
at or before thrombopoesis by the platelet precursor cell, the MK.49 
MPV AND GENDER 
                    Gender-dependent differences in platelet count have been 
demonstrated in few studies. In women platelet count is higher than in men, 
which seems to reflect different hormonal profiles or a compensatory 
mechanism associated with menstrual blood loss. Studies shows that there is 
no statistically significant differences in the mean platelet volume, though 
there was a slight increase in females.50 
MPV AND HYPERTENSION 
                                       The effects of SNS over activity on the 
platelets occur in two possible ways.  
1. Alpha 2-adrenoreceptor stimulation causes shape change of platelets 
directly and thereby increases MPV.51 
2.  Activated larger platelets which are sequestered in the spleen can be 
released into the circulatory system following the increased levels of 
adrenaline thereby contributing to increased MPV levels        
                                       Mean platelet volume (MPV), a determinant of 
platelet function, is a newly emerging risk factor for atherothrombosis. Coban 
E et al52 selected 36 essential hypertensive patients, 36 white coat hypertensive 
subjects and 36 normotensive control subjects matched for age, gender, and 
body mass index. MPV was very significantly higher in essential 
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hypertensives and white coat hypertensives than in normotensives (P < 0.00); 
it was also higher in essential hypertensives than in white coat hypertensives 
(P < 0.05). Platelet counts were not different among the study groups (P > 
0.05). MPV was positively correlated with ambulatory diastolic blood pressure 
in essential hypertension and white coat hypertension groups (P < 0.05). 
Platelet size is also found to be elevated in individuals with hypertension and 
diabetes mellitus, both conditions that predispose to the development of 
vascular diseases. 
MPV AND DIABETES MELLITUS 
                                 Zuberi B F et al53 conducted this cross-sectional 
study at Dow University of Health Sciences, Karachi, Pakistan between the 
period of September 2006 and May 2007. Sample size of 204 in each group 
was calculated using power (1-beta) of 90 percent and level of significance 
(alpha) at five percent. Confirmed patients with DM, IFG and non-diabetic 
controls were selected and allocated to respective groups. A total of 612 
patients were selected and allocated to three groups of 204 patients each, 
referred to as DM group, IFG group and non-DM group. Fasting blood 
glucose, platelet counts and MPV were done. Mean MPV in the DM group 
was 9.34 fl, in the IFG Group was 8.98 fl, and in the non-DM group was 8.63 
fl. Comparison of MPV values for the three groups showed statistically 
significant intergroup and intragroup differences, with a p value of 0.00. MPV 
was significantly increased in the IFG group, as compared to the non-DM 
group, and it increased further when compared to the DM and IFG groups. 
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MPV AND ISHCEMIC HEART DISEASE 
                                        M M Khandekar, A S Khurana et al54 studied a 
total of 210 cases, 94 patients had unstable angina (UA) or acute myocardial 
infarction (AMI) diagnosed on the basis of history, characteristic 
electrocardiographic changes, and increased cardiac enzyme activities. 
Seventy patients had stable coronary artery disease (stable CAD) or were 
admitted for a coronary angiography or coronary artery bypass graft 
procedure. The third group comprised 30 age and sex matched healthy 
controls with no history of heart disease and a normal electrocardiogram. All 
PVI—mean platelet volume (MPV), platelet distribution width (PDW), and 
platelet large cell ratio (P-LCR)—were significantly raised in patients with 
AMI and UA (mean MPV, 10.43 (SD, 1.03) fL; mean PDW, 13.19 (SD, 2.34) 
fL; mean P-LCR, 29.4% (SD, 7.38%)) compared with those with stable CAD 
(mean MPV, 9.37 (SD, 0.99) fL; mean PDW, 11.35 (SD, 1.95) fL; mean P-
LCR, 22.55% (SD, 6.65%)) and the control group (mean MPV, 9.2 (SD, 0.91) 
fL; mean PDW, 10.75 (SD, l.42) fL; mean P-LCR, 20.65% (SD, 
6.14%)).Larger platelets are haemostatically more active and are a risk factor 
for developing coronary thrombosis, leading to myocardial infarction. Patients 
with larger platelets can easily be identified during routine haematological 
analysis and could possibly benefit from preventive treatment. 
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MATERIALS AND METHODS 
PATIENT SELECTION: 
                                 All participants of study were explained about the 
hypertension and its complications. They were informed about the study 
proceedings and the usefulness of the study in their own language. All the 
subjects gave consent before participating in the study. 
STUDY CENTRE  
 Institute of Internal Medicine, 
 Rajiv Gandhi Government General Hospital, 
 Chennai. 
DURATION OF THE STUDY  
                    1 year (September 2017 to August 2018) 
STUDY DESIGN  
                    Cross sectional study 
SAMPLE SIZE  
               A total of 150 participants comprising 50 normotensives & 100 
hypertensive (50 Controlled hypertensives and 50 Resistant hypertensive) 
patients. Healthy subjects who attended routine master health checkups 
were taken as normotensive group. 
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INCLUSION CRITERIA: 
1. Age >30 years & < 60 years 
2. Normotension : SBP < 120 mmHg and DBP <80 mmHg without any 
antihypertensive medications. 
3. Hypertension :  
a. Controlled hypertension : SBP <140 mmHg and DBP < 90 mmHg with 
three or fewer antihypertensive drugs of different class 
b. Resistant hypertension : SBP  ≥140 mmHg and/or DBP ≥ 90 mmHg 
with ≥3 different class of antihypertensive medications or requiring ≥ 4  
antihypertensive medications to achieve the goal of SBP <140 mmHg and 
DBP < 90 mmHg, in which one of the antihypertensive should be diuretic 
in optimum dosage. 
EXCLUSION CRITERIA: 
1. Age < 30 years &  ≥ 60 years  
2. Known haematological abnormalities (Thrombocytopenia, ITP, 
myeloid leukemias, Bernard soulier syndrome)  
3. Chronic renal failure ( cr > 1.5 mg/dl ) 
4. Peripheral arterial diseases  
5. Diabetes mellitus 
6. Coronary artery disease 
7. Patients on anticoagulant drugs 
8. Hypertensive patients with known poor adherence to treatment 
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METHODOLOGY 
                           After obtaining clearance and approval from the 
institutional ethics committee and written informed consent in their own 
language of the caregiver, patients admitted to medical wards and in those 
patients attending hypertension OPD & routine master health check-up 
during September 2017 to August 2018 at Rajiv Gandhi government 
general hospital, Chennai were selected after fulfilment of inclusion and 
exclusion criteria and enrolled in the study.  They were subjected to the 
following  
1. Detailed patient history 
2. General examination including vitals, weight and height recording 
3. Systemic examination 
4. Laboratory investigations 
5. Electrocardiogram  
 
HISTORY  
A detailed history were elicited, includes 
¾ Age 
¾ Sex 
¾ Duration of hypertension 
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¾ Detailed antihypertensive medication history including number, name 
and dosage. 
¾ Drugs for hypertension and their dose 
¾ History of chest pain, pedal edema, oliguria 
¾ History of headache, giddiness, blurring of vision 
¾ History of abdomen distention, jaundice, bleeding manifestation 
¾ History of claudication pain 
¾ History of other comorbidities like diabetes mellitus, Thyroid disorders, 
Chronic kidney disease, coronary artery disease 
¾ Any other treatment history like antiplatelets, anticoagulants 
¾ History of smoking & alcohol  
¾ Menstrual history for females 
GENERAL EXAMINATION 
                                   Detailed general examination was done including 
weight in kgs and height in metres. BMI was calculated using formula 
weight in kg divided by height in metre square. 
MEASUREMENT OF BLOOD PRESSURE 
             Patient is allowed to sit in a chair in such a way his/her both feet 
should touch the floor and back should be supported well and make 
him/her relax for more than 5 minutes. They must have been advised to 
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avoid caffeine, exercise and smoking for atleast 30 minutes before blood 
pressure measurement. Have to ensure he/she emptied bladder. Preferably 
neither examiner nor patient should talk in rest period. Clothing should be 
removed from arm area where cuff to be tied. With patient’s arm supported 
at desk, validated sphygmomanometer is used. Position the middle of the 
cuff on upper arm at the level of right atrium. Correct sized cuff, such that 
bladder part covers 80% of arm circumference and 40% of arm length is 
used. Lower border of the cuff should be atleast 1-2 cm above elbow 
crease. First a palpated estimate of systolic BP is measured at radial artery, 
then cuff is inflated 20-30 mmHg above that value to confirm by 
auscultation method over cubital fossa. The rate of deflation of cuff should 
be 2mmHg per second. Record SBP and DBP based on appearance and 
disappearance of korotkoff sounds. BP is measured in both arms, then arm 
with higher value is used for further readings. Two measurements with 
minimum gap of two minutes are taken at two different occasions, then 
above values average is taken as final reading. All the above said rules 
were follows during BP measurement. 
SYSTEMIC EXAMINATION  
Then patients were subjected to Systemic examination of the following 
systems 
¾ Cardiovascular system 
¾ Respiratory system 
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¾ Abdomen  
¾ Central nervous system 
                            
INVESTIGATIONS: 
          Venous blood samples were collected from all participants after 
overnight fasting to do haemoglobin, platelet count, mean platelet volume 
(Mean platelet volume was measured using fully automated hematology 
analyzer - Sysmex XN-1000), serum triglyceride level, fasting blood sugar, 
post prandial blood sugar, serum creatinine, liver function test, peripheral 
smear as mentioned in proforma were performed. Early morning urine 
albumin creatinine ratio was calculated and those patients with ACR > 
300mg/gm were excluded. 
                 From above information furnished after subjecting to inclusion 
and exclusion criteria subjects were categorized to any one of the category 
as mentioned normotension, controlled hypertension or resistant 
hypertension group. From above all data collected, statistical analysis was 
done using SPSS software version 17.0 
CONFLICT OF INTEREST 
 None 
SPONSORSHIP 
No 
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RESULTS 
 
FREQUENCY OF DISTRIBUTION OF STUDY POPULATION 
 
Group Frequency Percent 
Normotension 50 33.3 
Controlled 
Hypertension 50 33.3 
Resistant 
Hypertension 50 33.3 
Total 150 100.0 
 
33%
33%
33%
Normotensives
Controlled Hypertensives
Resistance Hypertensives
 
 
INTERPRETATION: 
The above table depicts the number of normotensive subjects, CHTN and 
RHTN patients frequency and its percentage included in our study. They were 
equally distributed in our study population. 
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FREQUENCY OF DISTRIBUTION ACCORDING TO AGE GROUP 
 
 
Age group Frequency Percent 
30-39 Years 18 12.0 
40-49 Years 48 32.0 
50-59 Years 84 56.0 
Total 150 100.0 
 
12%
32%56%
Distribution according to age group
30‐39 Years
40‐49 Years
50‐59  Years
 
 
INTERPRETATION: 
The above table depicts the age group of patients among the 150 study 
samples, the 18(12%) belongs to the age group of 30-39 years, 48 (32%) 
belongs to 40-49 years and remaining 84(56%) belongs to 50-59 years. 
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Crosstab 
 group Total 
Normote
--nsive  
Controlled 
Hypertensive 
Resistant 
Hypertensive 
Age 
group 
30-39 
Years 
Count 12 3 3 18 
%  66.7% 16.7% 16.7% 100.0% 
40-49 
Years 
Count 19 17 12 48 
%  39.6% 35.4% 25.0% 100.0% 
50-59 
Years 
Count 19 30 35 84 
%  22.6% 35.7% 41.7% 100.0% 
Total 
Count 50 50 50 150 
%  33.3% 33.3% 33.3% 100.0% 
Pearson Chi-Square=15.411  p=0.004 
 
 
The above table depicts the association between age and hypertension. 
The chi square value was statistically significant for the patients in the age 
group of 40-59 years. 
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FREQUENCY OF DISTRIBUTION ACCORDING TO GENDER 
 
Gender Frequency Percent 
Male 83 55.3 
Female 67 44.7 
Total 150 100.0 
 
 
 
INTERPRETATION: 
The above table depicts the gender of the participants, majority of the 
patients belongs to male 83(55%) and remaining 67(45%) were female. 
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 Group Total 
Normo
tensive 
Controlled 
Hypertensive 
Resistance 
Hypertensive 
sex 
Male 
Count 23 30 30 83 
% within sex 27.7% 36.1% 36.1% 100.0% 
Female 
Count 27 20 20 67 
% within sex 40.3% 29.9% 29.9% 100.0% 
Total 
Count 50 50 50 150 
% within sex 33.3% 33.3% 33.3% 100.0% 
Pearson Chi-Square=2.643  p=0.267 
The above table depicts the association between gender and hypertension. 
The chi square value was not statistically significant which shows that there 
is no gender difference among hypertensive patients. 
 
 
FREQUENCY OF DISTRIBUTION ACCORDING TO DURATION 
OF HYPERTENSION IN YEARS 
 
Duration of HTN in 
years 
Frequency Percent 
1-3 Years 42 42.0 
3-6 Years 37 37.0 
7-11 Years 21 21.0 
Total 100 100.0 
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42%
37%
21%
DISTRIBUTION ACCORDING TO DURATION OF HTN IN YEARS
1‐3 Years
3‐6 Years
7‐11 Years
 
Interpretation: 
The above table depicts the duration of hypertension of patients 
among the 100 hypertensives, 42(42%) were having hypertension for the past 
1-3 years, 37(37%) having HTN for 3-6 years and 21(21%) having 
hypertension for the past 7-11 Years. 
 
CORRELATION BETWEEN DURATION OF HYPERTENSION AND 
MPV 
 
Pearson correlation test r = 0.194; p = 0.053; 
From above picture, by using Pearson correlation test we found there is no 
significant association between MPV and duration of hypertension. 
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FREQUENCY OF DISTRIBUTION ACCORDING TO No. OF 
ANTIHYPERTENSIVE MEDICATIONS 
 
 
 
No.of AHTN drugs Frequency Percent 
1 9 9.0 
2 29 29.0 
3 18 18.0 
4 44 44.0 
Total 100 100.0 
 
 
 
INTERPRETATION: 
The above table depicts the distribution based on No. of AHTN 
medications the patients were on, among the 100 study samples. The majority 
of 44(44%) were on 4 different AHTN medications. 
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COMPARISION OF MPV WITH AGE IN ALL 3 GROUPS 
 
 
                                                                             MPV   
AGE N Mean Std.  
Deviation
Std.  
Error 
95% Confidence  
Interval for Mean 
Minim 
um 
Maxim 
um 
  
Lower 
Bound 
Upper 
Bound 
f value p value
30-39 Years 18 8.4722 0.90865 0.21417 8.0204 8.9241 6.90 10.70 4.383 0.014 
40-49 Years 48 8.9625 1.26552 0.18266 8.5950 9.3300 7.10 12.60 
50-59 Years 84 9.3440 1.24178 0.13549 9.0746 9.6135 6.90 12.30 
Total 150 9.1173 1.24312 0.10150 8.9168 9.3179 6.90 12.60 
 
 
INTERPRETATION: 
                       The above table depicts the MPV with age of study 
population. For the age groups of 30-39 years, 40-49 years, 50-59 years of 
age the mean of MPV is 8.472 (SD 0.90865), 8.9625 (SD 1.26552) and 
9.3440 (SD 1.24178) respectively. The F value is significant at p<0.05 and 
there is difference in MPV values in different age of the patients.  
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 COMPARISION OF MPV WITH AGE IN NORMOTENSIVE 
SUBJECTS 
 
 
MPV   
AGE N Mean Std. 
Deviation 
Std. Error 95% Confidence 
Interval for Mean 
Minim
um 
Maxim 
um 
  
Lower 
Bound 
Upper    
Bound 
f      
value
p 
value
30-39 
Years 
12 8.1750 0.81366 0.23488 7.6580 8.6920 6.90 9.40 
0.077 0.926
40-49 
Years 
19 8.2789 0.71692 0.16447 7.9334 8.6245 7.30 10.50 
50-59 
Years 
19 8.1737 1.13228 0.25976 7.6279 8.7194 6.90 10.60 
Total 50 8.2140 0.90057 0.12736 7.9581 8.4699 6.90 10.60 
 
 
INTERPRETATION: 
               The above table depicts the MPV of normotensive subjects. For 
age groups of 30-39 years, 40-49 years and 50-59 years of age the mean of 
MPV is 8.1750 (SD 8.1366), 8.2789 (SD 0.71692), 8.2140 (SD 1.13228) 
respectively. The F value is not significant, p>0.05 and there is no significant 
difference in MPV values among different age group of normotensive 
subjects. 
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COMPARISION OF MPV WITH AGE IN CHTN GROUP 
 
 
 
INTERPRETATION: 
                           The above table depicts the MPV of CHTN patients. For 
the age group of 30-39 years, 40-49 years, 50-59 years the mean value of  
MPV is 8.6667 (SD 0.40415), 8.6412 (SD 0.81091) and 9.1367 (SD 
0.81091) respectively. F value is not significant, p>0.05 and so there is no 
significant difference in MPV values among different age group of the 
CHTN patients. 
 
 
 
 
                                                                     MPV   
AGE 
(years) 
N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum   
Lower 
Bound 
Upper 
Bound 
f 
value 
p 
value 
30-39  3 8.6667 0.4041 0.2333 7.6627 9.6706 8.30 9.10 
 2.208  0.121 
40-49   17 8.6412 0.8109 0.1966 8.2242 9.0581 7.10 10.10 
50-59   30 9.1367 0.8109 0.1518 8.8262 9.4471 7.80 11.80 
Total  50 8.9400 0.8305 0.1174 8.7040 9.1760 7.10 11.80 
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  COMPARISION OF MPV WITH AGE IN RHTN GROUP 
 
                                                                      MPV   
AGE 
(years) 
N Mean Std. 
Deviation 
Std. Error 95% Confidence 
Interval for Mean 
Minimum Maximum   
Lower 
Bound 
Upper 
Bound 
f 
value
p 
value
30-39  3 9.4667 1.06927 0.61734 6.8105 12.1229 8.80 10.70 1.2180.305
40-49  12 10.5000 1.22474 0.35355 9.7218 11.2782 8.80 12.60 
50-59  35 10.1571 1.00595 0.17004 9.8116 10.5027 7.90 12.30 
Total 50 10.1980 1.06857 0.15112 9.8943 10.5017 7.90 12.60 
 
INTERPRETATION: 
                         The above table depicts the MPV of RHTN patients. For the 
age group of 30-39 years, 40-49 years and 50-59 years the mean value of  MPV 
is 9.4667 (SD 1.06927), 10.5000 (SD 1.2247) and 10.1571 (SD 1.01) 
respectively. The F value is not significant, p >0.05 and there is no significant 
difference in MPV values among different age group of the RHTN patients. 
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        COMPARISION OF GENDER WITH MPV AMONG ALL 3 
GROUPS 
 
 
sex N Mean Std. 
Deviation 
Std. Error 
Mean 
t value p value 
MPV 
Male 83 9.1072 1.20424 0.13218 0.110 0.912 
Female 67 9.1299 1.29872 0.15866 
 
INTERPRETATION: 
The above table depicts MPV with gender in our study population. The 
mean MPV for males (83) was 9.1072 (SD 1.20424); the mean MPV for 
females (67) was 9.1299 (SD 1.29872). The t value is not significant which 
shows that there is no significant gender difference in MPV. 
 
    COMPARISION OF GENDER WITH MPV IN NORMOTENSIVE 
GROUP 
 
 
sex N Mean Std. Deviation Std. Error 
Mean 
t value p value 
MPV 
Male 23 8.0957 0.87463 0.18237 0.865 0.397 
Female 27 8.3148 0.92641 0.17829 
 
INTERPRETATION: 
         The above table depicts the MPV with gender in normotensive subjects. 
The t value is not significant which shows that there is no significant difference 
in MPV values between both gender in normotensive group. 
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COMPARISION OF GENDER WITH MPV IN CHTN GROUP 
 
 
 
sex N Mean Std. Deviation Std. Error 
Mean 
t value p value 
MPV 
Male 30 8.9433 0.71616 0.13075 0.034 0.973 
Female 20 8.9350 0.99804 0.22317 
 
INTERPRETATION: 
The above table depicts the MPV with gender in CHTN patients. The t 
value is not significant which shows that there is no significant difference in 
MPV values in between both gender. 
 
COMPARISION OF GENDER WITH MPV IN RHTN GROUP 
 
 
sex N Mean Std. Deviation Std. Error 
Mean 
t value p value
MPV 
Male 30 10.0467 1.12026 0.20453 1.233 0.224 
Female 20 10.4250 0.96893 0.21666 
 
INTERPRETATION: 
The above table depicts the MPV with gender in RHTN patients. The t 
value is not significant which shows that there is no significant gender 
difference of MPV in RHTN group. 
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COMPARISION OF MPV AND BMI AMONG 3 GROUPS 
 
 
 
7.50
8.00
8.50
9.00
9.50
10.00
10.50
18.5‐24.99 25‐29.99 Above  30
8.43
9.11
10.02
COMPARISION OF MPV AND BMI AMONG 3 GROUPS
 
INTERPRETATION: 
The above table depicts the MPV with BMI of study population. For 
BMI of 18.5-24.99 (55) Kg/m2, 25-29.99(53) Kg/m2 and above 30(42) Kg/m2 
the mean MPV is 8.4345 (SD 0.80259), 9.1113 (SD 1.05314), 10.0190 SD 
1.37933) respectively. The F value is highly significant, P<0.001which shows 
that there is significant difference in MPV values in different BMI. MPV 
increases, as BMI increases. i.e., Obese peoples are having higher MPV than 
the non-obese patients. 
MPV   
BMI N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean
Minim 
um 
Maxim 
um 
  
Lower 
Bound 
Upper 
Bound 
f  
value
p value
18.5-
24.99 
55 8.4345 0.80259 0.10822 8.2176 8.6515 7.20 10.90 
25.781p<0.001
25-29.99 53 9.1113 1.05314 0.14466 8.8210 9.4016 6.90 11.80 
Above  
30 
42 10.0190 1.37933 0.21284 9.5892 10.4489 6.90 12.60 
Total 150 9.1173 1.24312 0.10150 8.9168 9.3179 6.90 12.60 
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COMPARISION OF MPV AND BMI IN NORMOTENSIVE GROUP 
 
MPV   
BMI N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
Minim
um 
Maximu
m 
  
Lower 
Bound 
Upper 
Bound 
f 
value
p 
value
18.5-24.99 30 8.1900 0.79323 0.14482 7.8938 8.4862 7.20 10.20 0.305 0.738 
25-29.99 14 8.3500 0.97724 0.26118 7.7858 8.9142 6.90 10.60 
Above  30 6 8.0167 1.30907 0.53443 6.6429 9.3905 6.90 10.50 
Total 50 8.2140 0.90057 0.12736 7.9581 8.4699 6.90 10.60 
 
INTERPRETATION: 
The above table depicts the BMI with MPV of normotensive subjects. 
The F value is not significant, P>0.05 which shows that there is no significant 
difference in MPV in different BMI in normotensive group. 
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COMPARISION OF MPV AND BMI IN CONTROLLED 
HYPERTENSION GROUP 
 
                                                                 MPV   
BMI N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
Minim
um 
Maximu
m 
  
Lower 
Bound 
Upper 
Bound 
f 
value
p 
value
18.5-24.99 16 8.4312 0.36827 0.09207 8.2350 8.6275 7.70 8.90  
7.118
0.002 
25-29.99 21 9.0000 0.89107 0.19445 8.5944 9.4056 7.10 10.40 
Above  30 13 9.4692 0.81791 0.22685 8.9750 9.9635 8.60 11.80 
Total 50 8.9400 0.83054 0.11746 8.7040 9.1760 7.10 11.80 
 
INTERPRETATION: 
The above table depicts the BMI with MPV of controlled HTN patients. 
The F value is highly significant, P<0.001which shows that there is significant 
difference in MPV values in different BMI. Obese peoples having higher MPV 
Values than the non-obese patients in CHTN group. 
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COMPARISION OF MPV AND BMI IN RESISTANT HYPERTENSION 
GROUP 
 
 
 
INTERPRETATION: 
                                  The above table depicts the BMI with MPV of RHTN 
patients. The F value is highly significant, P<0.001which shows that there is 
significant difference in MPV values in different BMI. Obese peoples having 
higher MPV Values than the non-obese in resistant hypertension group.
                                                              MPV   
BMI N Mean Std. 
Deviation 
Std. Error 95% Confidence 
Interval for Mean 
Minimu
m 
Maximu
m 
  
Lower 
Bound 
Upper 
Bound 
f value p value 
18.5-24.99 9 9.2556 0.91120 0.30373 8.5551  9.9560 7.90  10.90 13.309 p<0.001 
25-29.99 18 9.8333   0.82676 0.19487 9.4222 10.2445 8.60 11.80 
Above  30 23 10.8522 0.89080 0.18574 10.4670 11.2374 9.00  12.60 
Total 50   10.1980 1.06857    0.15112  9.8943 10.5017 7.90  12.60 
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         COMPARISION OF MPV AND SBP AMONG 3 GROUPS 
 
                                                                             MPV  
SBP 
mmHg 
N Mean Std. 
Deviation
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
F value
<120 69 8.3420 0.87471 0.105308.1319 8.5522 6.90 10.60 44.353 
120-139 31 9.1000 0.86410 0.155208.7830 9.4170 7.70 11.80 
140-159 39 9.9615 0.93122 0.149119.6597 10.2634 7.90 12.30 
 160 & 
above 
11 11.03641.14392 0.3449010.2679 11.8049 8.80 12.60 
Total 150 9.1173 1.24312 0.101508.9168 9.3179 6.90 12.60 
**p<0.001 
 
 
 
0.00
2.00
4.00
6.00
8.00
10.00
12.00
<120 120‐139 140‐159 160 & above
8.34
9.10
9.96
11.04
MPV AND SBP 
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INTERPRETATION: 
The above table depicts the MPV with systolic blood pressure of study 
population. For SBP of <120 mmHg (69), 120-139 mmHg (31), 140-159 (39) 
and 160 and above (11) mmHg the mean value of MPV is 8.34 (SD 0.87), 9.10 
(SD 0.86), 9.96 (SD 0.93) and 11.0364 (SD 1.14) respectively. The F value is 
highly significant, P<0.001which shows that there is significant difference in 
MPV in different Systolic Blood pressure. MPV rises significantly as SBP 
rises. 
 
 
COMPARISION OF MPV AND SBP IN CHTN GROUP 
 
                                                                      MPV   
SBP 
(mmHg) 
N Mean Std. 
Deviation 
Std. Error 95% Confidence 
Interval for Mean
Minimu
m 
Maxim
um 
  
Lower 
Bound
Upper 
Bound 
T 
value 
p value
<120 19 8.6789 0.71924 0.16501 8.3323 9.0256 7.10 10.40 1.778 0.082 
120-139 31 9.1000 0.86410 0.15520 8.7830 9.4170 7.70 11.80 
Total 50 8.9400 0.83054 0.11746 8.7040 9.1760 7.10 11.80 
 
INTERPRETATION: 
The above table depicts the MPV against SBP of controlled HTN 
patients. The F value is not significant and there is no significant difference in 
MPV with different SBP in CHTN group. 
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COMPARISION OF MPV AND SBP IN RESISTANT HYPERTENSION 
GROUP 
 
                                                                   MPV   
SBP 
(mmHg) 
N Mean Std. 
Deviation
Std. 
Error 
95% Confidence 
Interval for Mean 
Mini
mum
Maxim 
um 
  
Lower 
Bound 
Upper 
Bound 
T 
value 
p 
value 
140-159 39 9.9615 0.93122 0.14911 9.6597 10.2634 7.90 12.30 3.215 0.002 
160 & 
above  
11 11.0364 1.14392 0.34490 10.2679 11.8049 8.80 12.60 
Total 50 10.1980 1.06857 0.15112 9.8943 10.5017 7.90 12.60 
 
 
 
INTERPRETATION: 
                   The above table depicts the MPV with SBP of RHTN patients. The 
F value is highly significant, P<0.001which shows that there is significance 
difference in MPV values in different Systolic Blood pressure . So in resistant 
hypertensive patients MPV increases, as SBP increases. 
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CORRELATION OF MPV AND DBP AMONG 3 GROUPS 
 
                                                                                    MPV  
DBP 
mmHg 
N Mean Std. 
Deviation
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
 F 
value 
<80 75 8.4040 0.94504 0.10912 8.1866 8.6214 6.90 11.80 42.652
80-89 28 9.0393 0.69567 0.13147 8.7695 9.3090 7.70 10.20 
90-99 25 10.0560 0.58813 0.11763 9.8132 10.2988 9.00 10.90 
100 & 
above 
22 10.5818 1.29565 0.27623 10.0074 11.1563 8.60 12.60 
Total 150 9.1173 1.24312 0.10150 8.9168 9.3179 6.90 12.60 
**p<0.001 
0.00
2.00
4.00
6.00
8.00
10.00
12.00
<80 80‐89 90‐99 100 & above
8.40 9.04
10.06 10.58
 
 
INTERPRETATION: 
The above table depicts the MPV with DBP of study subjects. For DBP 
<80 mmHg (75), 80-89 mmHg (28), 90-99 mmHg (25), above 100(22) mmHg 
the mean value of MPV is 8.404 (SD 0.945), 9.039 (SD 0.695), 10.0560 (SD 
0.58813) and 10.5815 (SD 1.29565) respectively. The F value is highly 
significant, P<0.001which shows that there is significant difference in MPV 
values in different diastolic Blood pressure. MPV increases, as DBP increases. 
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COMPARISION OF MPV AND DBP IN CONTROLLED 
HYPERTENSION GROUP 
 
 
                                                               MPV   
DBP 
mmHg 
N Mean Std.  
Deviation 
Std. Error 95% Confidence 
Interval for Mean 
Minimum Maximum   
Lower 
Bound 
Upper 
Bound 
T  
value
p value 
<80 25 8.7840 0.93393 0.18679 8.3985 9.1695 7.10 11.80 1.339 P=0.187 
80-90 25 9.0960 0.69671 0.13934 8.8084 9.3836 7.70 10.20 
Total 50 8.9400 0.83054 0.11746 8.7040 9.1760 7.10 11.80 
 
INTERPRETATION: 
The above table depicts the MPV with DBP of CHTN patients. The F 
value is not significant, P>0.05which shows that there is no difference in MPV 
values in different diastolic Blood pressure in controlled hypertension patients. 
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COMPARISION OF MPV AND DBP IN RHTN GROUP 
 
                                                                  MPV   
DBP 
mmHg 
N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minim
um 
Maximu
m 
  
Lower 
Bound 
Upper 
Bound 
f value p value 
80-89 3 8.5667 0.57735 0.33333 7.1324 10.0009 7.90 8.90  6.233** P=0.004 
90-99 25 10.0560 0.58813 0.11763 9.8132 10.2988 9.00 10.90 
100 
&above 
22 10.5818 1.29565 0.27623  10.0074 11.1563 8.60 12.60 
Total 50 10.1980 1.06857 0.15112   9.8943 10.5017 7.90 12.60   
 
0.00
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COMPARISION OF MPV AND DBP IN RHTN GROUP
 
INTERPRETATION: 
The above table depicts the MPV with DBP of RHTN patients. The F 
value is highly significant, P<0.001which shows that there is significant 
difference in MPV values in different diastolic Blood pressure in resistant 
hypertensive patients. MPV rises as DBP increases. 
75 
 
COMPARISION OF MPV AND SERUM CREATININE AMONG 3 
GROUPS 
 
                                                                     MPV   
Sr Cr 
(mg/dl) 
N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean
Minim
um 
Maximu
m 
  
Lower 
Bound
Upper 
Bound 
f value p value
<0.6 29 8.6000 0.97468 0.18099 8.2293 8.9707 7.10 10.40 4.451 P=0.013
0.6-1.2 111 9.1901 1.25893 0.11949 8.9533 9.4269 6.90 12.60 
>1.2 10 9.8100 1.34036 0.42386 8.8512 10.7688  7.90 11.80 
Total 150 9.1173 1.24312 0.10150 8.9168 9.3179 6.90 12.60   
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INTERPRETATION: 
                                 The above table depicts the MPV with serum creatinine in 
study population. For Sr. Cr < 0.6 mg/dl(29) , 0.6-1.2 mg/dl(111), >1.2 
mg/dl(10)  the mean value of MPV is 8.6000 (SD 0.97468), 9.1901 (SD 
1.25893) and 9.8100 (SD 1.34036) respectively. The F value is significant, 
P<0.05 which shows that there is significant difference in MPV values in 
different serum creatinine level. MPV is positively correlated to serum 
creatinine. 
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COMPARISION OF MPV AND SERUM CREATININE IN 
NORMOTENSIVE SUBJECTS 
 
                                                                             MPV   
Sr Cr 
(mg/dl) 
N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean
Minimum Maximum   
Lower 
Bound
Upper 
Bound 
f 
value
p 
value
<0.6 
 17  8.1471 0.87258 0.21163  7.6984 8.5957 7.10 10.20 
0.391 0.678 
0.6-1.2 
 31  8.2161 0.94625 0.16995  7.8690 8.5632 6.90 10.60 
>1.2 
 2  8.7500 0.21213 0.15000 6.8441 10.6559 8.60 8.90 
Total  50  8.2140 0.90057 0.12736 7.9581 8.4699 6.90 10.60 
  
 
 
INTERPRETATION: 
The above table depicts the MPV with serum creatinine in normotensive 
group. The F value is not significant, which shows there is no correlation 
between MPV and Sr Cr in normotensive subjects. 
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COMPARISION OF MPV AND SERUM CREATININE IN CHTN 
GROUP 
 
                                                                     MPV 
  
Sr Cr 
(mg/dl) 
N Mean Std. 
Deviation
Std. 
Error 
95% Confidence 
Interval for Mean
Minimum Maximum   
Lower 
Bound
Upper 
Bound 
f value p value
<0.6 
8 8.9750 0.61354 0.21692 8.4621 9.4879 8.00 9.90 0.265 0.769 
0.6-1.2 
40 8.9125 0.85611 0.13536 8.6387 9.1863 7.10   11.80 
>1.2 
2 9.3500 1.48492 1.05000 -3.9915 22.6915 8.30  10.40 
Total 50 8.9400 0.83054 0.11746 8.7040 9.1760 7.10  11.80   
 
INTERPRETATION: 
The above table depicts the MPV with serum creatinine in CHTN group. 
The F value is not significant, p > 0.05 which shows there is no significant 
correlation between them. 
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COMPARISION OF MPV AND SERUM CREATININE IN RESISTANT 
HYPERTENSIVE GROUP 
 
                                                             MPV   
Sr Cr 
(mg/dl) 
N Mean Std. 
Deviation
Std. 
Error 
95% 
Confidence 
Interval for 
Mean 
Minimum Maximum   
Lower 
Bound
Upper 
Bound
f 
value
p 
value
<0.6 4 9.7750 0.74106 0.370538.595810.9542 8.80 10.40 0.3510.706
0.6-1.2 40 10.2225 1.05939 0.167509.883710.5613 8.60 12.60 
>1.2 6 10.3167 1.39344 0.568878.854311.7790 7.90 11.80 
Total 50 10.1980 1.06857 0.151129.894310.5017 7.90 12.60   
 
INTERPRETATION: 
The above table depicts the MPV with serum creatinine RHTN patients. 
The F value is not  significant, p >0.05 shows there is no significant correlation 
between them. 
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COMPARISION OF MPV AND TGL AMONG 3 GROUPS 
 
                                                                  MPV   
Sr TGL N Mean Std. 
Deviation
Std. 
Error 
95% 
Confidence 
Interval for 
Mean 
MinimumMaximum   
Lower 
Bound
Upper 
Bound
f value p value
<150 58 8.7741 1.02795 0.13498 8.5039 9.0444 6.90 10.90 33.761P<0.001
150-200 66 8.8212 0.99298 0.12223 8.5771 9.0653 6.90 10.90 
>200 26 10.6346 1.15687 0.22688 10.167311.10198.70 12.60 
Total 150 9.1173 1.24312 0.10150 8.9168 9.3179 6.90 12.60   
 
0.00
5.00
10.00
15.00
8.77 8.82
10.63
m
pv
<150                                      150‐200                                           >200 
MPV WITH TGL AMONG 3 GROUPS
 
INTERPRETATION: 
The above table depicts the MPV with TGL in all 3 groups. Patients 
with Sr.TGL <150 mg/dl (58), 150-200 mg/dl(66), TGL >200 mg/dl (26) the 
mean value of MPV is 8.7741 (SD 0.02795), 8.8212 (SD 0.99298) and 10.6346 
(SD 1.15687). The F value is significant, P<0.05which shows that there is 
significant difference in MPV values in different TGL  levels. MPV is higher in 
those patients with higher serum triglyceride levels. 
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COMPARISION OF MPV AND TGL IN NORMOTENSIVE GROUP 
 
                                                                MPV   
Sr TGL 
(mg/dl) 
N Mean Std. 
Deviation
Std. 
Error 
95% Confidence 
Interval for 
Mean 
MinimumMaximum  
Lower 
Bound 
Upper 
Bound 
f 
value 
p value
<150 22 8.2227 0.91440 0.19495 7.8173 8.6281 6.90 10.20 7.917 P<0.001
150-200 25 8.0000 0.64161 0.12832 7.7352 8.2648 6.90 9.60 
>200 3 9.9333 1.06927 0.61734 7.2771 12.58958.70 10.60 
Total 50 8.2140 0.90057 0.12736 7.9581 8.4699 6.90 10.60   
 
 
INTERPRETATION: 
The above table depicts the MPV with TGL in normotensive subjects. 
The F value is significant, P<0.05which shows that there is significant 
difference in MPV values in different TGL level. MPV is higher in those 
patients with higher triglyceride levels even among normotensive subjects. 
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COMPARISION OF MPV AND TGL IN CONTROLLED 
HYPERTENSIVE GROUP 
 
                                                                      MPV   
Sr 
TGL 
(mg/dl)
N Mean Std. 
Deviation
Std. 
Error 
95% 
Confidence 
Interval for 
Mean 
MinimumMaximum   
Lower 
Bound
Upper 
Bound
f 
value 
p value
<150 23 8.73040.76303 0.159108.40059.0604 7.10 10.10 4.880P=0.012
150-
200 
21 8.91430.69447 0.151558.59829.2304 7.90 10.40 
>200 6 9.83331.05198 0.429478.729310.93739.00 11.80 
Total 50 8.94000.83054 0.117468.70409.1760 7.10 11.80   
 
INTERPRETATION: 
The above table depicts the MPV with TGL in patients of CHTN group. 
The F value is significant, P<0.05which shows that there is significant 
difference in MPV in different TGL  level. MPV is higher in patients with 
higher triglyceride levels in CHTN group.  
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COMPARISION OF MPV AND TGL IN RESISTANT HYPERTENSIVE 
GROUP 
. 
                                                             MPV   
TGL 
(mg/dl)
N Mean Std. 
Deviation
Std. 
Error 
95% 
Confidence 
Interval for 
Mean 
MinimumMaximum   
Lower 
Bound
Upper 
Bound
f value p value
<150 13 9.7846 0.90632 0.25137 9.2369 10.3323 7.90 10.90 11.443 P<0.001
150-
200 
20 9.7500 0.73520 0.16440 9.4059 10.0941 8.80 10.90 
>200 17 11.0412 1.04586 0.2536610.503411.5789 8.90 12.60 
Total 50 10.1980 1.06857 0.15112 9.8943 10.5017 7.90 12.60   
 
INTERPRETATION: 
The above table depicts the MPV with TGL in RHTN group. The F 
value is significant, P<0.05which shows that there is significant difference in 
MPV values in different TGL level.  
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POST HOC DUNNET T TEST 
Dependent 
Variable 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
BMI 
Controlled 
Hypertensive Normotensive 0.278 0.81431 0.919 
-
1.5408 2.0968 
Resistance 
Hypertensive Normotensive 2.97200* 0.81431 0.001 1.1532 4.7908 
Sr.Cr 
Controlled 
Hypertensive Normotensive 0.16400* 0.05818 0.011 0.0341 0.2939 
Resistance 
Hypertensive Normotensive 0.23600* 0.05818 0 0.1061 0.3659 
MPV 
Controlled 
Hypertensive Normotensive 0.72600* 0.18771 0 0.3067 1.1453 
Resistance 
Hypertensive Normotensive 1.98400* 0.18771 0 1.5647 2.4033 
Tgl 
Controlled 
Hypertensive Normotensive 4.82 5.65753 0.603 
-
7.8188 17.4588
Resistance 
Hypertensive Normotensive 15.04857* 5.68632 0.017 2.3454 27.7517
*. The mean difference is significant at the 0.05 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
 
The above table depicts the there is significant difference between BMI, 
serum creatinine, MPV, triglycerides, hemoglobin by using ANOVA , F value  
shows that there is significance difference among the groups p<0.05. Resistant 
hypertensive patients are having higher BMI, serum creatinine, triglycerides 
and lower hemoglobin, but no difference in platelet count by using Post hoc. 
By Dunnet t test there is difference in serum creatinine, MPV between 
normotensives and controlled and resistance hypertension patients.  For BMI 
and triglyceride level no difference between normotensive and controlled 
hypertensive patients 
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Correlations between No of years of HTN with BMI, Sr Cr, platelet count, MPV , TGL 
 
 
                               The above table depicts the correlation between duration of 
HTN in years with BMI, serum creatinine, platelet count, MPV, serum 
triglycerides. Pearson correlation value was not statistically significant which 
shows that no correlation between them. 
 
 
 
 
  BMI Sr.Cr 
Platelet 
count MPV TGL 
HTN Pearson 
Correlation 
-0.003 -0.140 0.126 -0.185 -0.100 
Sig. (2-
tailed) 
0.979 0.164 0.211 0.066 0.325 
N 100 100 100 100 100 
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GROUP 
Mean 
95% Confidence 
Interval for Mean 
Median 
Std. 
Deviation Minimum Maximum 
Lower 
Bound 
Upper  
Bound 
 
 
Age 
Normotensive 46.4400 44.1721 48.7079 46.5000 7.97997 31.00 59.00 
Controlled 
Hypertensive 
51.4800 50.0013 52.9587 52.0000 5.20298 38.00 59.00 
Resistant 
Hypertensive 
52.0200 50.6002 53.4398 53.0000 4.99588 37.00 59.00 
 
 
BMI 
Normotensive 24.3380 23.1607 25.5153 23.7500 4.14251 17.90 32.90 
Controlled 
Hypertensive 
26.6380 25.4966 27.7794 26.6000 4.01614 19.30 33.90 
Resistant 
Hypertensive 
29.4420 28.3503 30.5337 29.8000 3.84145 22.60 38.80 
 
 
Sr Cr 
Normotensive 0.6440 0.5578 0.7302 0.6000 0.30315 0.20 1.30 
Controlled 
Hypertensive 
0.8080 0.7338 0.8822 0.8000 0.26096 0.40 1.40 
Resistant 
Hypertensive 
0.8800 0.7929 0.9671 0.9000 0.30639 0.20 1.40 
 
 
SBP 
Normotensive 114.9200 112.7497 117.0903 114.0000 7.63675 100.00 128.00 
Controlled 
Hypertensive 
123.6000 121.0477 126.1523 124.0000 8.98070 106.00 138.00 
Resistant 
Hypertensive 
155.2400 153.0375 157.4425 154.0000 7.75008 142.00 172.00 
 
 
DBP 
Normotensive 77.2000 75.2992 79.1008 78.0000 6.68840 64.00 88.00 
Controlled 
Hypertensive 
79.0400 77.2090 80.8710 81.0000 6.44271 66.00 88.00 
Resistant 
Hypertensive 
100.6000 98.6369 102.5631 100.0000 6.90755 90.00 118.00 
 
 
Platelet 
count 
Normotensive 2.9740 2.7644 3.1836 2.9850 0.73747 1.54 4.50 
Controlled 
Hypertensive 
2.7280 2.5054 2.9506 2.6100 0.78339 1.55 4.37 
Resistant 
Hypertensive 
2.7832 2.6109 2.9555 2.8300 0.60632 1.59 4.23 
 
 
MPV 
Normotensive 8.2140 7.9581 8.4699 8.1000 0.90057 6.90 10.60 
Controlled 
Hypertensive 
8.9400 8.7040 9.1760 8.8000 0.83054 7.10 11.80 
Resistant 
Hypertensive 
10.1980 9.8943 10.5017 10.3000 1.06857 7.90 12.60 
 
 
Tgl 
Normotensive 154.3800 147.1700 161.5900 155.5000 25.36983 104.00 216.00 
Controlled 
Hypertensive 
159.8000 151.5656 168.0344 156.0000 28.97430 117.00 224.00 
Resistant 
Hypertensive 
177.3800 167.9380 186.8220 183.5000 33.22336 110.00 235.00 
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DISCUSSION 
                  In our study we primarily assessed the mean platelet volume 
variation among patients with resistant hypertension, controlled hypertension 
and healthy normotensives.  
                 We studied on 50 patients in each group, so that there was equal 
frequency of distribution in all the 3 groups (i.e, 33% in all the 3 groups) 
 
DISTRIBUTION OF AGE: 
                Our study population included 150 patients comprising, 18 (12%) in 
30-29years of age, 48 (32%) in 40-49 age group and 84 (56%) in 50-59 years 
of age group. By inter & intra group analysis the distribution according to age 
is 66.7% (12), 16.7% (3), 16.7% (3) in 30-39 years of age group; 39.6% (19), 
35.4% (17), 25% (12) in 40-49 years of age group; 22.6% (19), 35.7% (30), 
41.7% (35) in 50-59 years of age group in normotensive, CHTN & RHTN 
group respectively.  
                    The mean age is 46.4 (SD of 9.7, median 46.5) years, 51.48 (SD of 
5.20, median 52) years, 52.02 (SD of 4.99, median 53) years for 
normotensives, controlled hypertensives and resistant hypertensives 
respectively. This shows prevalence of hypertension, particularly resistant 
hypertension increases with age, which was similar with previous studies.  
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DISTRIBUTION OF GENDER: 
                              Our study population comprising 150 subjects, had 55.3% 
(83) males and 44.7% (67) females. It includes 23 (27.7%), 30 (36.1%), 30 
(36.1%) males in normotensives, controlled hypertensives and resistant 
hypertensives group respectively. Similarly there were 27 (40.3%), 20 (29.9%), 
20 (29.9%) females in NTN, CHTN and RHTN group respectively. Thus our 
study, we observed a slightly increased number of male participants but it was 
statistically not significant (Pearson Chi-Square=2.643, p=0.267). Therefore, 
we observed that both males and females were almost equally affected, 
especially in the middle age.  
DURATION OF HYPERTENSION: 
                  Among 100 hypertensive participants including both CHTN & 
RHTN group, we divided them into three groups with duration of 1-3 years 
(42%), 4-6 years (37%), 7-11 (21%) years respectively. This shows our study 
population mainly consists of recent hypertensives, this may be due to 
excluding geriatric population of age above 60 years. To find correlation 
between duration of HTN in years with BMI, serum creatinine, platelet count, 
MPV and serum triglyceride Pearson correlation test was done, but value was 
not statistically significant which shows that there is no correlation between 
them. Similarly, there is no significant association between MPV and duration 
of hypertension. (p = 0.053) 
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NO. OF ANTIHYPERTENSIVE MEDICATIONS: 
                Among 100 hypertensive population we studied, majorly 44% were 
on 4 different antihypertensive agents, 18% were on 3 drugs, 29% were on 2 
different class of drugs and 9% were on single antihypertensive medications. 
This is due to the reason that half of our hypertensive population were resistant 
hypertensives. 
MEAN PLATELET VOLUME  
                  We observed mean value of MPV for healthy normotensive subjects 
is 8.21 (SD 0.90, median 8.1), for controlled hypertensives 8.94 (SD 0.83, 
median 8.8 ), for resistant hypertensives 10.20 ( SD 1.06, median 10.3 ) shows 
statistically significant ( F value – 57.185 , P < 0.001) difference in MPV 
among each group. This shows MPV is significantly higher in CHTN group 
compared to normotensives; and RHTN group has significantly higher MPV 
compared to both above mentioned groups. This is similar to results observed 
by Ozgur Surgit et al51. 
MPV WITH AGE: 
                            By detailed intra group analysis of all three groups, there is no 
significant statistical correlation (F value- 0.077, 2.208, 1.218; P value - 0.93, 
0.12, 0.31 for NTN, CHTN and RHTN groups respectively) between MPV and 
age. But intergroup analysis shows MPV increases significantly with age (F 
value – 4.38, P value 0.01, this is due to effect of hypertensive population 
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distribution increased with increasing age, which is similar to results observed 
by Verdola M et al60. 
SYSTOLIC BLOOD PRESSURE: 
                       On detailed analysis on whole study population to correlate MPV 
with SBP, we found MPV rises significantly (F value 44.35, P <0.001) as 
Systolic BP rises. By intragroup analysis this significant correlation (F value 
3.22, p = 0.002) is seen in RHTN group only, and p value is not significant (F 
value 1.78, p value 0.08) for CHTN group. From our observation MPV in 
RHTN group with SBP of 140-160 mmHg is 9.96 (SD - 0.93) and for above 
160 mmHg is 11.03 (SD - 1.14), which is significantly higher. Thus SBP may 
be an independent risk factor for high MPV which was similar to results 
observed in studies like Ozgur Surgit et al51. 
DIASTOLIC BLOOD PRESSURE: 
                      From our observations, it is clearly evident that MPV is 
significantly higher (F value = 42.65, p value <0.001) in those with high 
diastolic BP. It is confirmed by intra group analysis too, that MPV is higher as 
DBP rises in RHTN, but not in CHTN group. 
BMI: 
               On analyzing whole participants there is significant increase in MPV 
as BMI increases. Mean MPV for BMI below 24.99 is 8.43 (SD 0.80), 25.00 -
29.99 is 9.11 (SD 1.05) and for BMI above 30 is 10.02 (SD 1.38) with f value 
25.78, p value <0.001. Intra group analysis shows mean value of MPV as 8.21 
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(SD 0.90), 8.94 (SD 0.83), 10.19 (SD 1.06) for NTN, CHTN and RHTN groups 
respectively. The mean BMI for NTN, CHTN and RHTN groups are 24.32 (SD 
4.15) kg/m2, 24.60 (SD 3.43) kg/m2, 27.78 (SD 4.55) kg/m2 respectively with 
significant f value of 8.13, p <0.001. So, high BMI may be an independent risk 
factor for higher MPV. 
SERUM TRIGLYCERIDES LEVEL: 
           We observed mean value of Sr TGL is 154.38 (SD 25.37), 159.20 (SD 
28.24), 169.43 (SD 31.03) in NTN, CHTN and RHTN groups respectively with 
significant f value of 3.65, p value = 0.029. Similarly, in patients with Sr.TGL 
<150mg/dl the mean MPV value is 8.77 (SD 1.03), for TGL level 150-200 
mg/dl it is 8.82 (SD 0.99), for TGL >200 mg/dl it is 10.6346 (SD 1.16) and the 
F value is significant, P<0.05which shows that there is significant difference in 
MPV values in different TGL level and higher MPV is seen in patients with 
higher triglyceride levels. . So, high TGL may be an independent risk factor for 
higher MPV.  
MPV AND SERUM CREATININE: 
                     We divided our whole participants into three groups as those 
having Sr. Cr <0.6, 0.6-1.2, above 1.2 mg/dl , their mean values of MPV is 8.6 
(SD 0.98) , 9.19 (SD 1.26) , 9.81 (SD 1.34) respectively with significant f value 
of 4.45 and p value = 0.01 shows that MPV rises as serum creatinine rises. The 
mean Sr Cr is 0.64 (SD 0.30) mg/dl, 0.81 (SD 0.26)mg/dl , 0.88 (SD 0.31) 
mg/dl with f value 8.644, p value <0.001 for NTN, CHTN and RHTN groups 
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respectively; shows there is positive correlation between sr creatinine and 
MPV, and may be independent risk factor for high MPV. 
PLATELET COUNT: 
                         The mean platelet count in NTN, CHTN and RHTN groups are 
2.97 (SD 0.74) lakhs, 2.73 (SD 0.78) lakhs, 2.78 (SD 0.61) lakhs/cubic mm 
respectively with f value 1.64 and p value 0.20 (>0.05) showing that there is no 
correlation between MPV and platelet count. 
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CONCLUSION 
 From our study on 50 normotensive subjects and 100 hypertensives 
including 50 controlled hypertensives and 50 resistant hypertensive 
patients (in adults not including geriatric population), we concluded that 
mean platelet volume is significantly higher in resistant hypertensives than 
in controlled hypertensives and normotensives.  
 Apart from this we also found that prevalence of resistant hypertension 
increases with age.  
 There is no significant gender difference among hypertensives. 
 Positive correlation is found between Systolic blood pressure, Diastolic 
blood pressure, Body mass index, serum triglyceride level & serum 
creatinine level with MPV and resistant hypertension independently.  
 There is no significant correlation between duration of hypertension with 
MPV, BMI, triglyceride level and Serum creatinine independently. 
 Thus by estimating mean platelet volume(MPV), a simple and cost 
effective test we can determine the high risk group for atherosclerotic 
events in future, among middle age resistant hypertensive patients who 
could possibly benefit from aggressive preventive treatment. 
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LIMITATIONS OF THE STUDY 
 
1. Clinic blood pressure measurement is not a gold standard as 24 hour 
ambulatory blood pressure monitoring. 
2. Study population we have taken was small, so we need larger studies in 
future to confirm correlation. 
3. Study population doesn’t include geriatric population as we did study 
only on middle age hypertensive patients. 
4. The etiologies for resistant hypertension were not studied. 
5. Long term follow up of the patients to study on morbidities and 
mortalities associated with those patients with elevated MPV, were not 
done. 
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PROFORMA 
NAME                                            
AGE/SEX                                       
IP/OP No. 
ADDRESS 
H/o of symptoms: 
Headache  
Giddiness  
Blurring of vision 
Pedal edema 
Oliguria 
Jaundice  
Abdomen distention 
Bleeding manifestations – petechieae / ecchymosis / menorrhagia 
Claudication pain 
Chest pain 
Dyspnoea 
 
 
Past history  : 
 
H/o hypertension -                  
 
if yes – treatment details including number of drugs, name and dosage 
 
             ACE inhibitors / ARB 
             Alpha blockers 
             Beta blockers 
             CCB 
             Diuretics  
             Nitrates  
             Aldosterone antagonists 
Others 
H/o diabetes  - 
H/o Thyroid disease -  
H/o chronic drug intake – 
If yes details 
H/o chronic kidney disease - 
 
Examination : 
Weight                                 
Height 
BMI 
 
VITALS : 
Pulse rate 
Respiratory rate 
BLOOD PRESSURE 
 
 Reading I Reading II Reading III mean 
SBP  (mmHg)     
DBP(mmHg)     
SYSTEMIC EXAMINATION:  
CVS 
RS 
ABDOMEN 
CNS 
 
Mean platelet volume (in fl) 
Platelet count (cells in lakhs/ cu.mm) 
Sr. Creatinine (mg/dl)  
Sr. Triglycerides level (mg/dl) 
Liver function test 
Peripheral smear 
Bleeding time - 
Blood sugar           FBS -                           PPBS -  
ABI -   
Urine ACR (mg/gm) -  
 
NORMOTENSION /CONTROLLED HYPERTENSION /  
 
RESISTANT HYPERTENSION 
 
 
 
 
 
 
INFORMATION SHEET 
We are conducting a study on “A STUDY ON MEAN PLATELET 
VOLUME IN SUBJECTS WITH NORMOTENSION & IN PATIENTS 
WITH CONTROLLED AND RESISTANT HYPERTENSION” among 
patients attending Rajiv Gandhi Government General Hospital, Chennai and for 
that your specimen may be valuable to us. 
           The purpose of this study is to determine mean platelet volume in 
normotensives and to compare it with hypertensive patients, including 
controlled and resistant hypertension. 
We are selecting certain cases and if you are found eligible, we may 
elicit history and clinical examination and using your blood samples to do 
certain tests which in any way do not affect your final report or management. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment. 
 
Signature of Investigator      Signature of Participant 
 
Date : 
Place :
  
ஆய்வு தகவல் தாள் 
ஆய்வுதைலப்பு : ரத்தத்தில் உள்ள தட்டணுக்களின் கனஅளைவ சrயான ரத்த 
அழுத்தம் உள்ளவƫகளிடமும், கட்டுப்படுத்தப்பட்ட மற்றும் கட்டுப்படுத்த முடியாத ரத்த 
அழுத்தம் உள்ேளாrடமும் கண்டறிந்து ஒப்பிடுதல்  
ஆய்வாளƫெபயƫ   :   மரு. அ. ரகுபதி 
ஆய்வுநிைலயம்   :   ெபாதுமருத்துவப்பிrவு 
         ெசன்ைன மருத்துவக் கல்லுr, ெசன்ைன – 3 
 இந்த ஆய்வில் தங்கைள பங்ேகற்க அைழக்கிேறாம். இந்த தகவல் 
அறிக்ைகயில் கூறப்பட்டிருக்கும் தகவல்கள் தாங்கள் இந்த ஆராய்ச்சியில் 
பங்ேகற்கலாமா ேவண்டாமா என்பைத முடிவு ெசய்ய உதவியாக இருக்கும். இந்த 
படிவத்தில் உள்ள தகவல்கள் பற்றி உள்ள சந்ேதகங்கைள நங்கள் தயங்காமல் 
ேகட்கலாம். 
 இதில் ரத்த அழுத்தத்திற்க்கும் தட்டணுக்களின் கனஅளவிற்க்கும் ெதாடƫபு 
உள்ளதா என்பைத கண்டறியும் ஆராய்ச்சி ெசய்கிேறாம். அதற்கு இரத்த 
பrேசாதைனயும் ரத்தஅழுத்த அளவ டும் அவசியம். அதற்கு தங்களது ஒத்துைழப்புத் 
ேதைவ. 
 நங்களும் இந்த ஆராய்ச்சியில் பங்ேகற்க நாங்கள் விரும்புகிேறாம். முடிவுகைள 
அல்லது கருத்துகைள ெவளியிடும்ேபாேதா அல்லது ஆராய்ச்சியின் ேபாேதா தங்களது 
ெபயைரேயா அல்லது அைடயாளங்கேளா ெவளியிடமாட்ேடாம் என்பைதயும் 
ெதrவித்துக் ெகாள்கிேறாம்.  
 இந்த ஆராய்ச்சியில் பங்ேகற்பது தங்களுைடய விருப்பத்தின் ேபrல் தான் 
இருக்கிறது. ேமலும் நங்கள் எந்த ேநரமும் இந்த ஆராய்ச்சியில் இருந்து 
பின்வாங்கலாம் என்பைதயும் ெதrவித்துக் ெகாள்கிேறாம். 
 இந்த சிறப்புப் பrேசாதைனகளின் முடிவுகைள ஆராய்ச்சியின் ேபாது அல்லது 
ஆராய்ச்சியின் முடிவில் தங்களுக்கு அறிவிப்ேபாம் என்பைதயும் ெதrவித்துக் 
ெகாள்கிேறாம். 
 
ஆரய்ச்சியாளƫைகெயாப்பம் :    பங்ேகற்பவrன்ைகெயாப்பம்/ 
       இடதுகட்ைடவிரல்ேரைக 
ேததி :        ேததி : 
 
 
  
PATIENT CONSENT FORM 
Study Detail : A STUDY ON MEAN PLATELET VOLUME IN 
SUBJECTS WITH NORMOTENSION & IN 
PATIENTS WITH CONTROLLED AND RESISTANT 
HYPERTENSION 
Study Centre :  Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
                                               Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above study. 
I have the opportunity to ask question and all my questions and doubts have 
been answered to my complete satisfaction. 
❏ 
b) I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights being 
affected. 
❏ 
c) I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will not 
need my permission to look at my health records, both in respect of current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the study I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of 
any data or results that arise from this study. 
❏ 
d) I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. 
❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo detailed clinical examination and blood 
investigations as required. 
❏ 
 
Signature of investigator 
Signature/Thumb impression                                              
Study investigator Name: 
  
 
ஆய்வு ஒப்புதல் படிவம் 
ஆய்வுதைலப்பு : ரத்தத்தில் உள்ள தட்டணுக்களின் கனஅளைவ சrயான ரத்த 
அழுத்தம் உள்ளவƫகளிடமும், கட்டுப்படுத்தப்பட்ட மற்றும் கட்டுப்படுத்த முடியாத ரத்த 
அழுத்தம் உள்ேளாrடமும் கண்டறிந்து ஒப்பிடுதல் 
ெபயƫ :        ேததி :  
வயது :               ெவளிேநாயாளிஎண் : 
பால் :        
ஆராய்ச்சி ேசƫக்ைகஎண் : 
இந்த ஆராய்ச்சியின் விவரங்களும் அதன் ேநாக்கங்களும் முழுைமயாக எனக்கு 
ெதளிவாக விளக்கப்பட்டது.  எனக்கு விலக்கப்பட்ட விஷயங்கைள நான் புrந்து 
ெகாண்டு நான் எனது சம்மதத்ைத ெதrவிக்கிேறன். 
  இந்த ஆராய்ச்சியில் எனக்கு ரத்த அழுத்தத்ைத அளவ டு ெசய்யவும், ரத்தப் 
பrேசாதைன, எக்ேகா மற்றும் அல்ட்ராெசௗண்ட் ஸ்ேகன் (புறெவாலி அலகீடு) 
பrேசாதைனக்கு மனமார சம்மதிக்கிேறன்.  ேமற்கண்ட பrேசாதைனயின் ேபாது 
ஏற்படக்கூடிய பின்விைளவுகைளயும் முழுவதும் உணƫந்து இந்த பrேசாதைனக்கு 
மனமார சம்மதிக்கிேறன். 
நான் ஆராய்ச்சியாளுடன் ஒத்துைழப்ேபன் என்றும், எனக்கு ஏற்படக்கூடிய 
அசாதாரண நிகழ்வுகள் பற்றியும் உடனடியாக ஆராய்ச்சியாளிடம் ெதrவிப்ேபன் என்று 
உறுதி கூறுகிேறன். இந்த ஆய்விலிருந்து எப்ேபாது ேவண்டுமானாலும் எக்காரணமும் 
கூறாமல் என்ைன விடுவித்துக் ெகாள்ளலாம் என்பைத அறிேவன். என்னிடம் இருந்து 
ெபறப்படும் தகவல்கைள அரசு, வைரமுைற அதிகாrகள் ஆகிேயாƫகளுடன் பகிƫந்து 
ெகாள்ள ஆராய்ச்சியாளருக்கு அனுமதி அளிக்கிேறன். என்னுைடய சிகிச்ைச 
கட்டுகைள பாƫைவயிட உrைம உண்டு. என்னுைடய தகவல்களின் அைடயாளம் 
ரகசியமாக ைவக்கப்படும் என்பைத அறிேவன். 
இந்த ஆராய்ச்சியில் பங்ேகற்க தன்னிச்ைசயமாக முழுமனதுடன் 
சம்மதிக்கிேறன். 
பங்ேகற்பவrன்ைகெயாப்பம் / ேரைக :       ஆய்வாளƫைகெயாப்பம் : 
பங்ேகற்பவrன்ெபயƫ :          ஆய்வாளƫெபயƫ : 
இடம் :         இடம் : 
ேததி :         ேததி:
  
MASTER CHART 
 
S.N Age sex HTN BMI Sr. 
Cr 
SBP DBP Plt cnt MPV Tgl 
1 45 M No 24.6 0.9 106 80 1.96 8.0 162 
2 57 M No 23.9 0.5 106 70 2.34 7.2 138 
3 59 F No 26.7 1.0 104 72 2.55 7.3 134 
4 42 F No 28.8 0.5 114 68 2.69 7.6 157 
5 44 F No 19.9 0.6 102 66 2.35 8.7 177 
6 56 M No 31.8 0.7 100 64 1.99 6.9 166 
7 55 M No 24.2 0.9 106 70 2.65 7.8 169 
8 53 M No 23.3 1.1 112 74 3.65 7.9 188 
9 42 F No 24.9 1.3 116 72 2.98 8.6 146 
10 45 F No 22.8 1.2 112 76 3.55 8.3 163 
11 56 M No 28.6 0.6 118 74 3.68 8.2 156 
12 45 M No 25.3 0.5 114 76 1.89 8.4 162 
13 34 M No 21.2 0.9 112 74 4.50 7.3 169 
14 47 F No 18.6 0.7 104 78 3.69 8.4 148 
15 36 M No 19.2 1.2 106 70 2.56 8.6 130 
16 31 M No 26.9 0.9 110 78 3.54 8.8 173 
17 32 M No 27.2 1.0 114 76 2.44 6.9 116 
18 56 F No 29.7 1.1 116 70 2.56 7.5 129 
19 53 F No 23.6 0.6 118 66 4.14 8.7 201 
20 52 F No 21.5 0.7 116 68 3.65 10.2 113 
21 43 M No 24.3 0.6 114 70 3.57 8.3 154 
22 41 F No 19.5 0.5 112 74 2.39 7.9 136 
23 42 M No 30.6 0.8 116 76 3.64 7.5 155 
24 47 F No 17.9 0.7 110 72 1.98 7.6 199 
25 39 F No 22.2 0.9 114 74 3.57 7.7 144 
26 46 F No 31.9 1.1 114 76 3.21 10.5 210 
27 53 M No 23.3 0.9 116 78 3.19 9.9 133 
28 58 M No 32.9 1.2 112 78 2.06 8.2 126 
29 45 M No 26.8 1.0 114 76 2.05 7.6 129 
30 42 F No 27.2 1.1 114 70 3.54 8.3 173 
31 48 F No 20.6 0.9 116 70 2.98 8.6 127 
32 38 F No 19.3 0.8 106 74 2.65 8.8 119 
33 37 M No 20.3 0.3 108 70 3.54 7.9 186 
   
  
S.N Age sex HTN BMI Sr. 
Cr 
SBP DBP Plt cnt MPV Tgl 
34 47 M No 28.8 1.1 110 72 3.68 8.8 104 
35 40 F No 30.3 1.0 118 76 2.56 7.9 154 
36 50 F No 27.6 1.2 116 74 2.14 8.9 143 
37 51 M No 22.1 0.6 114 70 1.88 7.6 162 
38 33 F No 21.5 0.9 118 78 1.65 7.2 158 
39 44 M No 19.9 0.5 114 76 1.54 8.0 163 
40 49 F No 20.5 0.8 112 72 2.95 7.3 145 
41 52 F No 31.0 1.0 116 70 2.67 7.1 127 
42 58 F No 23.3 0.6 112 74 3.58 7.3 185 
43 59 F No 18.8 0.6 106 72 2.99 7.3 169 
44 56 M No 20.5 0.8 108 68 3.54 7.4 141 
45 35 F No 18.9 0.9 108 74 3.68 9.2 166 
46 36 M No 27.9 1.1 110 76 4.05 8.4 160 
47 51 F No 20.3 0.6 114 84 2.99 8.6 128 
48 36 F No 20.9 0.8 116 82 3.65 9.4 133 
49 55 F No 26.5 0.9 114 76 3.88 9.6 177 
50 51 M No 27.6 0.8 118 76 3.54 10.6 216 
 
   
  
S.N Age sex HTN  
(in 
yrs) 
No of 
AHTD 
BMI Sr. 
Cr 
SBP DBP Plt cnt MPV Tgl 
1 45 F 2 3 23.1 0.6 130 84 2.33 10.1 188 
2 58 M 7 1 23.3 1.1 136 82 2.66 8.3 136 
3 52 M 5 2 24.6 0.9 120 74 3.54 8.9 120 
4 53 M 4 2 25.2 1.0 112 68 3.19 7.8 145 
5 59 F 9 3 26.0 0.9 136 88 1.69 8.0 119 
6 45 M 4 2 20.6 0.8 126 84 1.55 7.7 117 
7 52 F 8 2 25.6 1.1 128 82 3.60 8.4 186 
8 55 M 6 2 28.9 0.7 136 86 2.99 8.9 178 
9 38 M 1 2 32.3 0.4 124 74 3.01 9.1 214 
10 56 F 4 2 26.6 0.8 122 76 1.96 8.6 175 
11 56 M 8 3 19.9 0.6 108 66 2.65 8.8 137 
12 52 F 3 2 21.2 0.6 116 68 4.05 8.7 120 
13 57 F 5 2 26.6 1.1 132 82 3.65 9.5 196 
14 51 M 3 2 23.5 0.4 108 70 1.97 9.0 210 
15 38 M 1 1 27.9 1.0 116 80 2.63 8.3 197 
16 47 M 5 1 24.9 0.4 136 82 2.59 9.9 134 
17 58 M 7 1 28.1 0.6 138 84 3.62 10.2 212 
18 53 M 6 2 30.2 1.1 122 68 4.09 8.7 199 
19 56 F 9 1 24.3 0.5 124 72 3.58 8.8 143 
20 58 F 6 1 26.5 0.9 130 88 1.92 8.3 167 
21 54 M 8 2 21.8 0.5 134 86 1.86 9.5 204 
22 50 F 7 1 19.3 0.6 122 82 2.48 8.6 137 
23 49 M 5 1 24.4 0.9 106 70 2.69 7.9 189 
24 52 M 5 2 23.9 1.1 136 82 2.86 9.4 224 
25 48 M 3 2 19.7 1.0 120 84 3.29 9.1 164 
26 46 M 3 2 19.4 0.5 118 70 1.63 8.3 144 
27 47 M 4 3 21.5 0.8 116 68 2.06 8.5 149 
28 48 M 5 2 20.8 1.1 126 78 2.17 8.1 158 
29 56 F 5 2 21.5 0.6 120 84 1.55 8.6 162 
30 55 F 7 3 20.3 0.6 128 80 3.08 9.5 118 
31 59 F 11 2 26.6 1.0 136 84 3.65 10.2 166 
32 57 M 8 2 23.9 0.7 120 74 2.55 9.3 172 
33 54 M 6 3 24.9 0.8 114 70 2.11 9.5 133 
34 39 M 1 3 30.9 0.6 110 76 1.63 8.6 157 
35 46 F 2 2 20.8 0.4 122 88 2.35 8.8 168 
36 49 F 7 2 27.9 0.7 108 72 2.21 7.1 125 
37 48 F 3 2 27.4 0.8 126 80 3.51 8.1 167 
  
38 49 M 6 2 25.2 0.6 124 86 2.65 9.4 138 
39 56 M 6 3 28.3 0.5 130 84 2.47 9.2 165 
40 53 M 3 2 26.1 1.4 114 76 1.88 10.4 161 
41 52 M 3 2 20.6 0.9 138 86 1.69 10.1 148 
42 51 F 4 3 21.9 0.7 126 78 2.37 11.8 179 
43 57 F 4 2 32.1 1.0 118 88 2.55 9.1 150 
44 55 M 5 1 29.5 1.1 136 86 4.26 8.8 142 
45 56 F 9 3 26.9 0.8 130 82 3.59 9.6 131 
46 55 F 6 2 23.4 0.9 124 78 3.80 8.2 144 
47 47 M 3 2 20.1 1.1 128 76 2.57 9.6 138 
48 50 M 4 3 25.6 1.2 116 84 2.03 9.0 155 
49 49 M 2 2 21.4 0.5 112 80 4.37 8.0 139 
50 48 F 6 3 24.4 0.8 122 82 3.22 8.7 140 
   
  
S.N Age sex HTN  
(in 
yrs) 
No of 
AHTD
BMI Sr. 
Cr 
SBP DBP Plt cnt MPV Tgl 
1 55 F 3 4 22.3 0.5 150 92 3.22 10.8 159 
2 46 M 3 4 26.5 1.3 160 96 2.94 9.6 164 
3 42 M 3 4 24.9 1.2 152 98 1.77 9.2 148 
4 49 M 4 4 25.2 0.2 156 102 3.01 8.8 176 
5 56 M 4 4 27.0 1.0 148 96 2.60 9.0 119 
6 58 F 9 3 19.2 0.6 142 100 3.34 10.3 139 
7 53 F 5 4 28.3 0.8 156 102 2.29 10.6 177 
8 52 M 3 4 26.9 0.7 170 118 2.56 11.5 133 
9 40 F 2 4 30.6 1.0 172 114 3.22 8.8 172 
10 53 M 3 4 28.5 1.4 160 110 2.84 7.9 144 
11 58 M 10 3 28.8 0.8 148 98 3.29 8.9 151 
12 59 F 2 4 29.6 1.3 152 104 2.63 10.5 197 
13 48 M 2 4 27.3 1.2 150 102 2.88 10.9 N 
14 52 M 6 4 36.6 0.8 146 98 3.07 9.8 177 
15 55 F 3 4 24.0 1.1 148 96 1.59 12.3 169 
16 39 M 1 4 27.2 1.2 158 94 2.66 8.9 188 
17 55 M 2 4 23.6 0.8 160 114 3.36 10.9 201 
18 52 F 3 4 19.6 0.9 162 102 3.49 11.4 190 
19 37 M 2 4 24.6 1.0 148 94 2.93 10.7 130 
20 56 M 1 4 19.5 1.1 166 112 3.50 11.2 210 
21 53 M 2 4 23.3 0.9 170 116 2.78 9.8 119 
22 52 M 3 4 20.6 0.3 166 112 3.54 9.6 127 
23 58 F 3 4 23.8 0.5 154 104 2.35 8.9 154 
24 46 F 2 4 24.6 0.7 158 102 2.99 10.9 144 
25 51 F 7 4 27.3 0.9 160 112 4.23 9.5 179 
26 49 F 2 4 26.6 0.8 148 104 1.88 8.9 206 
27 57 M 9 3 27.6 0.6 152 96 2.15 9.7 196 
28 55 F 7 4 21.9 1.3 144 94 2.43 11.8 176 
29 57 M 6 4 23.9 0.6 148 98 3.69 10.8 122 
30 56 M 8 4 34.8 0.7 142 100 1.74 10.3 128 
31 53 M 7 4 24.6 0.6 152 110 2.82 8.9 223 
32 50 M 2 4 29.7 1.0 150 108 2.96 12.6 174 
33 56 F 6 4 26.3 0.7 160 104 4.02 10.7 207 
34 48 F 5 4 33.2 0.7 148 92 2.68 10.3 147 
35 54 M 2 4 26.9 1.2 146 96 1.66 9.9 189 
36 55 M 5 4 27.8 1.3 150 98 2.49 11.2 214 
37 48 F 4 3 37.6 1.0 158 102 3.61 10.3 156 
38 50 F 4 4 33.9 0.9 160 108 2.36 10.8 179 
  
39 57 M 5 4 32.6 0.6 148 100 1.88 10.1 207 
40 53 M 2 4 30.4 0.4 154 104 2.44 10.4 206 
41 52 M 2 3 21.4 1.0 150 106 3.33 8.6 110 
42 49 M 1 4 23.6 1.2 160 110 2.12 11.9 129 
43 56 F 3 4 29.7 0.2 146 96 2.45 10.3 178 
44 52 F 3 4 38.8 0.5 148 98 3.10 11.6 182 
45 51 M 5 4 26.9 1.0 152 100 2.88 9.0 190 
46 49 M 2 4 27.5 0.7 160 102 2.65 11.8 159 
47 53 M 6 3 26.8 0.5 146 100 1.95 9.7 197 
48 52 F 2 4 31.5 0.6 148 98 3.05 9.3 188 
49 56 F 6 4 33.1 1.0 154 96 2.66 10.5 235 
50 58 M 7 4 27.6 0.8 156 92 3.08 9.8 137 
 
UNITS FOR ABBREVIATION 
AHTD - Anti Hypertensive Drugs  
BMI  -  Kg/m2 
Sr.Cr  -  mg/dl 
SBP  -  mmHg 
DBP  -  mmHg 
Plt cnt  - Lakhs/mm3 
MPV  -  fL 
Tgl  –  mg/dl 
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